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Abstract 
Health related issues are largely regulated at EU Member State level, whereas areas such as internal market and competition 
fall mainly under the remit of European Union competence. This creates tension not only between legislation governing 
health and that concerning internal market but also between national and EU legislation. Here the Court of Justice of the 
European Union (CJEU) plays a key role in developing case-law through its judgments, defining further interpretation both 
on European and national level. An example of a sector operating at the interphase between public health and internal 
market interests is community pharmacy, which was chosen as the focus area of the study. 
 
The aim of this master’s thesis was, through the case-study example of the regulation of pharmacy establishment, ownership 
and distribution in EU Member States, to perform a documentary analysis on related CJEU judgments, focusing on 
statements present in them referring to public health and internal market, discussing potential impacts on the community 
pharmacy sector as well as relating the outcomes to the broader context of European health policy with reference to existing 
literature. The study material consisted of publicly available documentation related to four judgments (Case C-531/06, 
Joined Cases C-171/07 and C-172/07, Joined Cases C-570/07 and C-571/07 and Case C-367/12) that were made between 
the years 2009 and 2014, the first proceedings initiating in 2006. 
 
The prevalence and variety of statements related to public health were found to be much higher in the documents analysed 
compared to those relating to internal market. The most common argumentation present in the judgments was related to the 
statement that regulation of ownership of community pharmacies can be justified by public health reasons, deriving from the 
professionalism inherent to pharmacists as well as ensuring balance between public health and economic interests. This 
transmits a clear message of the importance of public health and indeed the Court has been perceived as a balancing force to 
the union’s liberalisation agenda.  
 
Following this it seems unlikely that the interpretation for national regulation would change in the near future, meaning that 
Member States should be able to maintain community pharmacy regulation, to the extent that it is implemented in a 
consistent manner. However, there has been indication of other routes being used to push for the liberalisation agenda and 
therefore it continues being a part of the debate both at European and national level. 
 
The findings of this study support literature suggesting that spillover is taking place in relation to the Court of Justice and 
health. Furthermore, it has been clearly demonstrated that even though officially the EU has very limited competence 
(authority) in health, its influence on European health policy is in fact highly significant, taking place to a large extent via 
routes other than those officially assigned to it in relation to health in particular. Whether this is intentional or unintentional, 
it does not change the fact that health policy is being influenced. When it happens without explicit intention, the processes 
lose transparency and are driven by other, potentially competing agendas. Therefore it would be important to assess whether 
the decision making processes and other processes currently shaping the European healthcare policy are in line with what 
was originally intended and re-evaluate whether this dynamic is the preferred way to proceed in the future. 
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Tiivistelmä 
Terveyteen ja terveydenhuoltoon liittyvä sääntely kuuluu pääasiassa Euroopan unionin (EU) jäsenmaiden päätäntävallan 
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ristiriidassa keskenään. Euroopan unionin tuomioistuimella (EUT) on tässä keskeinen rooli, kun se kehittää 
oikeuskäytännön kautta EU-sääntelyn tulkintaa. Tutkimuksessa keskityttiin apteekkisektoriin, joka on hyvä esimerkki 
kansanterveyden ja sisämarkkinoiden tavoitteiden ja lainsäädännön rajapinnassa toimivasta alasta. 
 
Tutkimuksen tavoite oli analysoida EUT:n tuomioihin liittyvää dokumentaatiota koskien apteekkien perustamisen, 
omistajuuden ja sijoittautumisen rajoittamista keskittyen niissä esiintyviin kansanterveyteen ja sisämarkkinoihin liittyviin 
lausuntoihin. Lisäksi tutkimuksessa arvioitiin mahdollisia seurauksia apteekkisektoria koskien sekä laajemmassa 
mittakaavassa EU:n terveyspolitiikkaan liittyen, viitaten myös olemassa olevaan kirjallisuuteen. Tutkimusaineisto koostui 
julkisesti saatavilla olevasta dokumentaatiosta neljään tuomioon liittyen (asia C-531/06, yhdistetyt asiat C-171/07 ja C-
172/07, yhdistetyt asiat C-570/07 ja C-571/07 sekä asia C-367/12), jotka annettiin vuosien 2009 ja 2014 välillä. 
Ensimmäisen asian käsittely alkoi vuonna 2006. 
 
Laadullisen dokumenttianalyysin avulla voitiin todeta, että EUT:n tuomioihin liittyvään dokumentaatioon sisältyi sekä 
laadultaan että määrältään merkittävästi enemmän kansanterveyttä koskevia lausuntoja kuin vastaavasti sisämarkkinoita 
koskevia lausuntoja. Dokumenteissa yleisimmin käytetty argumentaatio liittyi apteekkien omistajuuden rajoittamisen 
perustelemiseen kansanterveydellisillä syillä, jotka liittyivät sekä proviisorien ammatillisiin velvollisuuksiin että 
kansanterveydellisten ja taloudellisten intressien välisen tasapainon varmistamiseen. Tästä välittyy viesti 
kansanterveydellisten tavoitteiden tärkeydestä ja tuomioistuimen onkin tulkittu toimivan eräänlaisena vastavoimana unionin 
agendalle poistaa ylimääräinen sääntely jäsenmaissa. 
 
Edellä mainitusta johtuen on epätodennäköistä, että jäsenmaiden täytyisi muuttaa tämänhetkistä lainsäädäntöään apteekkien 
sääntelyyn liittyen, kunhan se on johdonmukaisesti implementoitu. Vaikuttaa kuitenkin siltä, että sääntelyn vähentämisen tai 
poistamisen tavoitteen saavuttamiseksi hyödynnetään enenevissä määrin myös muita kanavia, kuten poliittisia 
päätöksentekoprosesseja, joten keskustelu apteekkien sääntelystä tulee jatkumaan sekä kansallisella että EU-tasolla. 
 
Tutkimus tukee kirjallisuutta, jonka mukaan EUT:n toiminnassa olisi nähtävissä ”spillover”-ilmiön toteutumista 
kansanterveyteen liittyen. Tarkastellusta lähdekirjallisuudesta käy myös selvästi ilmi, että vaikka EU:lla ei virallisesti ole 
merkittävää toimivaltaa terveyteen liittyen, on sen vaikutusvalta eurooppalaisessa terveyspolitiikassa huomattava ja 
tapahtuu suurilta osin muiden kuin pääasiassa terveyteen liittyvien päätöksentekoprosessien kautta. Riippumatta siitä, onko 
tämä tarkoituksenmukaista vai ei, sen voidaan arvioida johtavan pahimmillaan päätösten läpinäkyvyyden heikentymiseen ja 
tilanteisiin, joissa muut tarkoitusperät ajavat terveyteen vaikuttavia prosesseja. Tämän vuoksi olisi tärkeä arvioida, 
vastaavatko tämänhetkiset EU:n terveyspolitiikkaan vaikuttavat päätöksentekoprosessit ja sääntely niiden alkuperäisiä 
tavoitteita ja halutaanko nykyisenkaltaista menettelyä jatkaa myös tulevaisuudessa. 
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DEFINITIONS OF KEY CONCEPTS 
The definitions provided are in the context of this study 
 
Case-law 
Judgments of the Court of Justice of the European Union contribute to a body of case-
law, creating precedents to how future similar cases should be resolved (i.e. future legal 
interpretation and court cases should follow the argumentation and logic from previous 
case-law), at least until they are overridden by new case-law, new legislation or a treaty 
change (Court of Justice of the European Union 2014; Greer et al. 2014). 
Argumentation in a judgment may also establish new principles to legislative practice. 
 
Commission  
The European Commission is the body responsible for drafting European Union 
legislation and monitoring its implementation (European Union 2014). The Commission 
represents the interests of the union and in its work aims at promoting the competences 
under which the EU Member States have given it a mandate to work, such as internal 
market. 
 
Community pharmacy 
Community pharmacies (“pharmacies”) are establishments providing pharmaceutical 
services including the provision of medicinal products and the associated patient 
counselling as well as other services and products depending on the country and 
pharmacy at question. The importance of role of community pharmacies as a part of 
healthcare systems and public health in “ensuring that the provision of medicinal 
products to the public is reliable and of good quality” has been recognised on national 
as well as European level leading to aspects of the sector being regulated (Vogler et al. 
2006) (see also: “Regulation”). 
 
Court of Justice 
The Court of Justice of the European Union has the highest mandate to interpret EU 
legislation (Court of Justice of the European Union 2014; Greer et al. 2014). It plays a 
crucial role in resolving contradictions between national and EU legislation through its 
 judgments and establishing precedence for future interpretation, especially in cases 
where EU legislation is not clear or lacking. The Court of Justice has been referred to as 
one of the most powerful courts in the world. 
 
De-regulation or liberalisation 
In the context of this study, de-regulation or liberalisation refers to actions taken on EU 
Member State level to reduce or remove existing national regulation on the community 
pharmacy sector (see also: “Regulation”). 
 
Establishment 
Establishment refers to the establishment of new community pharmacies. This is 
regulated in some EU Member States. For example, if a license is needed to start 
operating a new pharmacy it might be regulated regarding who can obtain such a license 
(ownership) or where a new pharmacy may be established (distribution) based on 
different criteria such as geographical or population based needs (Vogler et al. 2006) 
(see also: “Regulation”). 
 
Internal market 
In the context of the European Union, the concept of internal market is crystallised in 
the “fundamental freedoms” enshrined in the union treaties (Articles 34, 45, 49 and 57 
Treaty on the Functioning of the European Union). The fundamental freedoms consist 
of freedom of establishment, freedom to provide services and free movement of goods, 
services and workers. As internal market forms such an essential part of the aims behind 
the EU, the Commission has been given a strong mandate to facilitate its realisation 
within the union, and has done so through various initiatives, some of which are further 
addressed in this study. 
 
Member State 
Member State refers to a country that is a part of the European Union. Currently there 
are 28 EU Member States (European Union 2014). These member States maintain their 
own national legislations and healthcare systems, which may vary substantially across 
the continent. However through signing Treaties on the union they have also agreed to 
 give part of their sovereignty to the EU, meaning that in areas that have been commonly 
agreed, the EU may develop legislation that the Member States must follow. National 
governments implement and transpose EU legislation to national legislation and 
national courts together with the Court of Justice of the European Union help in 
interpreting any potential contradictions or inconsistencies. 
 
Public health 
Public health has been defined in a number of different ways and its organisation and 
implementation varies widely across the EU. In general it is understood to cover a range 
of issues spanning from preventive aspects (such as cancer prevention or smoking 
cessation programs) to health systems support, microbiological research and so on 
(Greer and Kurzer 2013). 
 
Regulation 
In the context of this study regulation refers mainly to Member State regulation on the 
community pharmacy sector. This can include regulation of establishment of new 
pharmacies, distribution of pharmacies, ownership of pharmacies, training of 
pharmacists and other pharmacy staff, tasks of pharmacists (services that can be 
provided) and products that can be distributed from a pharmacy (distribution of 
medicinal products) (Vogler et al. 2006). However, the main focus of this study is on 
national regulation in relation to establishment, ownership and distribution of 
pharmacies.  
 
It should also be noted that EU legislation that is directly related to community 
pharmacies regulates mainly on the professional qualifications of pharmacists (who may 
work in community pharmacies) and some of their core tasks, specifically leaving the 
set up of healthcare systems and community pharmacy regulation to the Member States 
to decide upon (Directive 2005/36/EC). 
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NOTE TO READER 
 
Unless otherwise noted the text in this study refers to the consolidated versions of the 
European Treaties, including the Treaty on European Union (TEU) and the Treaty on 
the Functioning of the European Union (TFEU) (Official Journal of the European Union 
C 326 of 26 October 2012). It should be noted that several of the cases included in the 
study refer to the Treaty establishing the European Community (TEC) and its respective 
numbering - where appropriate, article numbering for both treaties has been included for 
added clarity.   
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AESGP – the Association of the European Self-Medication Industry 
CJEU – Court of Justice of the European Union (previously ECJ) 
DG – Directorate-General 
DG COMP – Directorate-General for Competition 
DG GROW – the Directorate-General for Internal Market, Industry, Entrepreneurship  
                         and SMEs1 
DG MARKT – Former Directorate-General for Internal Market and Services  
DG SANCO – Former Directorate-General for Health and Consumers 
DG SANTE – Directorate-General for Health and Food Safety 
EAFP – European Association of Faculties of Pharmacy 
EAHP – European Association of Hospital Pharmacists 
EC – European Community or European Communities 
EFPIA – European Federation of Pharmaceutical Industries and Associations 
EGA – European Generic and Biosimilar medicines Association 
EMA – European Medicines Agency 
EP – European Parliament 
EPHA – European Public Health Alliance 
EPSA – European Pharmaceutical Students’ Association 
EU – European Union 
GIRP – the European Association of Pharmaceutical Full-line Wholesalers 
MS – EU Member State  
OTC – Over-the-counter 
PGEU – Pharmaceutical Group of the European Union 
TEC – Treaty establishing the European Community 
TEU – Treaty on the European Union 
TFEU – Treaty on the Functioning of the European Union 
  
                                                
1 “SMEs” refers to “small and medium sized enterprises” 
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 1 
1 INTRODUCTION 
 
Health related issues are largely regulated at Member State level, whereas areas such as 
internal market and competition fall mainly under the remit of EU competence. This 
creates tension not only between legislation governing health and that concerning 
internal market but also between national and EU legislation.  
 
At the interphase of all this are community pharmacies, which on one hand provide 
health services to the public and are an integral part of health care and on the other hand 
are also profit-making businesses, subject to similar rules as any other undertakings in 
the European Union.  
 
The role of community pharmacies in the safe and reliable provision of medicinal 
products has been increasingly recognised as an important contributor to public health. 
Consequently aspects of the community pharmacy sector have been subjected to 
regulation in some Member States, including regulation of establishment of new 
pharmacies, distribution of pharmacies, ownership of pharmacies, training of 
pharmacists and other pharmacy staff, tasks of pharmacists (services that can be 
provided) and products that can be distributed from a pharmacy (distribution of 
medicinal products).  
 
EU legislation clearly states that it is up to Member States to decide how they wish to 
set up their healthcare systems. However, as some of the national regulations affecting 
community pharmacies hinder competition and internal market principles, sometimes 
even creating professional monopolies, it has been questioned, whether the stated public 
health objectives justify sometimes relatively high levels of regulation. The debate on 
maintaining regulation versus liberalising the community pharmacy sector has 
continued both at national and European level and has led to various actions including 
several cases brought before the Court of Justice of the European Union. 
 
The Court of Justice of the European Union plays a central role in developing new 
interpretation of EU law and smoothing the gaps between national and supranational 
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governing. Until the end of the year 2014, there have been four cases where issues 
related to community pharmacy regulation (establishment, ownership or distribution) 
have been taken to the Court of Justice and resulted in a judgement. As the 
argumentation established in case law must be followed in similar future cases, these 
judgments have consequently shaped interpretation of community pharmacy regulation 
and potentially influenced public health policy on a larger scale as well. 
 
This qualitative study aims to make a critical analysis of the Court of Justice documents 
related to its judgments referring to the case-study example of the regulation of 
community pharmacy establishment, ownership and distribution in EU Member States 
by looking at statements linked to public health and internal market that are present in 
them.  
 
The secondary aim is to discuss their potential impacts on national and European level 
as well as in the broader context of the role of the Court of Justice in EU health policy, 
linking to previous research undertaken in this area. 
 
Identified need for this study: 
 
Even though references exists analysing various Court of Justice judgments in relation 
to health, according to a preliminary literature search, there still seems to be a need for a 
systematic analysis from the perspective of community pharmacy regulation. To some 
EU Member States, such as Finland, who maintain high community pharmacy 
regulation, the direct implications are evidently of interest. On a more general level, 
increasing the understanding of the dynamics between the different EU institutions as 
well as with the Member States and their development through the cases analysed, will 
hopefully prove to be helpful to professionals working with European health issues or 
people with general interest in the topic under study and assist in improving these 
processes.  
 
  
 3 
2 HEALTH IN EU POLICY AND LEGISLATION 
 
Before looking at health in EU policy in particular, it would be useful to clarify the roles 
of the core EU institutions and their decision-making processes. 
 
2.1 EU institutions and other actors involved in decision-making 
 
The core EU institutions involved in decision-making are the European Council, the 
European Commission, the Council and the European Parliament (Borchardt 2010; 
Cini and Pérez-Solórzano Borragán 2010; European Union 2014). The Commission, 
Parliament and Council receive advice from the European Economic and Social 
Committee (EESC) and the Committee of Regions (CoR) in the form of opinions to 
the decision-making process (Article 13 TEU). Also, technical, scientific or managerial 
functions are performed by specialised European agencies, which can also influence EU 
policy, even though they do not have legislative power. The specialised agency related 
to the pharmaceutical sector is the European Medicines Agency (EMA).  
 
There exist several other bodies and individuals outside the EU structure that can also 
influence European decision-making, such as specialised interest groups.  
 
2.1.1 The European Commission 
 
The European Commission (“Commission”) drafts the EU legislation and is in charge 
of following up its implementation at Member State level. Thus, its work could be 
compared to that of national governments at Member State level (Cini and Pérez-
Solórzano Borragán 2010; European Commission 2014a; European Union 2014). There 
are set time limits within which Member States (“MSs”) should implement EU 
legislation, depending on the type of legislation, and if this does not take place within 
the time limit the Commission can initiate a process called an infringement proceeding 
(Article 258 TFEU, ex Article 226 TEC), escalating the case to the Court of Justice of 
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the European Union if necessary (Court of Justice of the European Union 2014; 
European Commission 2014b; European Union 2014).  
 
The Commission is divided into departments with specific policy portfolios, called 
Directorate-Generals (“DGs”) (Cini and Pérez-Solórzano Borragán 2010; European 
Commission 2014a). The most important DGs in terms of this research include the 
Directorate-General for Health and Food Safety (“DG SANTE”2), the Directorate-
General for Internal Market, Industry, Entrepreneurship and SMEs (“DG GROW”3) and 
the Directorate General for Competition (“DG COMP”), following the Commission 
restructuring taking place at the end of 2014 (European Commission 2014c).  
 
Usually each DG has a Commissioner in charge of it, and in 2014 the concept of 
Commission Vice Presidents was also introduced to improve the working structure of 
the Commission, i.e. lead the Commissioners in charge of DGs in a more project-like 
manner. There is one Commissioner from each EU Member State, forming together the 
College of Commissioners (“College”) (Cini and Pérez-Solórzano Borragán 2010; 
European Commission 2014 a; European Commission 2014c). The College is headed 
by the Commission President, whose political role has been noted to strengthen in terms 
of leading the College and therefore the Commission (Article 17 TEU) (Kurpas et al. 
2008; Borchardt 2010).  
 
In addition, the Commissioners take political advice from their personal staffs 
(cabinets), who then coordinate horizontally with the other cabinets prior to the weekly 
meeting of the College of Commissioners as well as vertically with the officials 
working in the DG (services) (Cini and Pérez-Solórzano Borragán 2010; European 
Union 2014).  
 
The services should also work horizontally (interservice consultation) in order to ensure 
that whatever is proposed is in line with other existing policies and follows the 
                                                
2 Former Directorate-General for Health and Consumers (“DG SANCO”)  
3 Merged from both the former Directorate-General for Internal Market and Services (“DG MARKT”) 
and the former Directorate-General for Enterprise and Industry (“DG ENTR”) 
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principles of the standing Treaties and that therefore the Commission policies are 
aligned. Ultimately the College also functions under the principle of collegiality 
meaning that all Commissioners are responsible for all DGs.  
 
In the EU decision-making structure the Commission represents the interests of the EU, 
as opposed to interests of the Member States or individual EU citizens. Commissioners 
are supposed to be completely independent (Article 17(3) TEU) and not take advise 
from national governments (Borchardt 2010; Cini and Pérez-Solórzano Borragán 2010; 
European Union 2014).  
 
However this has been criticised, because it is the Member States that propose the 
Commissioner representing their country, often with a strong background in national 
politics (Borchardt 2010; Cini and Pérez-Solórzano Borragán 2010). In addition, the 
personal staffs of the Commissioners (cabinets) often consist of a high number of 
compatriots, usually interacting with the permanent representations of the countries in 
Brussels to exchange knowledge. In general it seems that once abroad, nationality 
becomes a common factor that is both intentionally and unintentionally used in order to 
build ties and rapport in European politics.  
 
People working for the Commission and involved in the legislative process can work for 
example as permanent staff under the Directorate-Generals, which are further divided 
into units, as experts in expert groups providing substance knowledge essential for 
drafting legislation or within the personal cabinets of the commissioners (Cini and 
Pérez-Solórzano Borragán 2010; European Union 2014).  
 
2.1.2 The Council of the European Union 
 
The Council of the European Union (or the “Council”) consists of ministers of the 
national governments of the EU Member States (Borchardt 2010; Cini and Pérez-
Solórzano Borragán 2010; Council of the European Union 2014b; European Union 
2014). The Council can meet in ten different configurations depending on the topic of 
the meeting. For example if the Council needs to discuss issues related to finance, the 
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finance ministers or equivalent of each Member State would meet together and so forth 
(Council of the European Union 2014a). Health related issues are addressed by the 
Member States’ ministers of health at the Employment, Social Policy, Health and 
Consumer Affairs Council.  
 
In the EU decision-making structure the Council represents the interests of the Member 
States (Borchardt 2010; Cini and Pérez-Solórzano Borragán 2010; Council of the 
European Union 2014b; European Union 2014). It has a rotating six-month presidency 
that is held by one Member State at a time. During their presidency the Member State 
holds and chairs council meetings and also has the chance to lift certain priority policy 
topics on the table, which can also be health related. In order to ensure consistency in 
the work of the council, collaboration takes place within groups of three consecutive 
presidencies (“trios”), i.e. between three Member States, to create 18-month joint 
programmes with agreed agendas. 
 
Each Member State has permanent representations in Brussels, with people (“permanent 
representatives” or “perm reps”) working to advocate for their national interests 
(Borchardt 2010; Cini and Pérez-Solórzano Borragán 2010; Council of the European 
Union 2014b; European Union 2014). They form the Committee of Permanent 
Representatives of the Governments of the Member States to the European Union 
(Coreper), which prepares the work of the Council together with more than 150 
specialised committees and working parties (“Council preparatory bodies”) (Council of 
the European Union 2014b). Working parties relevant for health are, for example, 
the Working Party on Public Health and the Working Party on Pharmaceuticals 
and Medical Devices.  
 
Even though each council configuration addresses issues from a specific perspective, 
the ministers attending that specific council meeting should represent a consensus view 
of their national government and ensure national level communication (European Union 
2014; Greer et al. 2014). Additionally, a General Affairs Council has been set up to 
ensure consistency between the portfolios of the different council configurations. 
 7 
Regardless of the aforementioned, the work of the Council has received criticism for 
being fragmented. 
 
2.1.3 The European Parliament 
 
The European Parliament (the “Parliament” or “EP”) was historically introduced later, 
only in the 1970’s, into the EU decision-making structure in order to bring decision-
making closer to the European citizens and to increase transparency (Borchardt 2010; 
Cini and Pérez-Solórzano Borragán 2010; Council of the European Union 2014 a; 
European Union 2014; Greer et al. 2014). Therefore the Parliament represents the 
interests of individual people and the representatives (Members of the European 
Parliament, or “MEPs”) are chosen via direct election.  
 
Since its establishment, the power of the Parliament has grown steadily from being 
merely a body providing supervision and scrutiny to becoming a substantial part of the 
decision making process with an increasing amount of issues being subject to the 
ordinary legislative procedure (also called the “co-decision procedure”) it is part of. In 
addition, the Parliament has growing powers related to the EU budget, the right to hold 
hearings on different issues, veto candidates for President of the Commission and 
question the Commissioners (Cini and Pérez-Solórzano Borragán 2010; European 
Union 2014; Greer et al. 2014). 
 
The Members of the European Parliament organise themselves into party groups that 
are largely similar to those existing in the majority of the Member States (European 
Parliament 2014; European Union 2014; Greer et al. 2014). The concrete work takes 
place mainly through the standing committees for various policy areas (currently 20 
standing committees), which lead the Parliament’s work in each specific area. For 
different topics there is a rapporteur and shadow rapporteur nominated from within the 
committee members (MEPs), who prepare a report on behalf of the Parliament. These 
reports are revised by the committee as a whole as well as the Parliament as a whole.  
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The committee concerned with health is the Environment, Public Health and Food 
Safety Committee (“ENVI committee”) (European Parliament 2015), however 
several other committees deal with issues impacting health as well, like the Industry, 
Research and Energy Committee (for example in relation to health research) and the 
Employment and Social Affairs Committee (dealing for example with social security 
coordination). 
 
2.1.4 The European Medicines Agency 
 
The European Medicines Agency (EMA) is a decentralised specialised agency of the 
European Union responsible for evaluating and supervising medicines for human and 
animal use (Cini and Pérez-Solórzano Borragán 2010; European Public Health Alliance 
2013; European Medicines Agency 2014). 
 
Its main tasks include for example the following  
(Source: European Medicines Agency 2014): 
 
• Scientific evaluation of Marketing Authorisation applications for the centralised 
procedure in the EU (grants marketing authorisation in EU and EEA countries) 
• Pharmacovigilance (safety-monitoring) for medicines in the EU 
• Referrals (scientific assessments of specific medicines or classes on medicines, 
can be requested either by Member States or the Commission) 
• Coordinating inspections related to good manufacturing practice (“GMP”), good 
clinical practice (“GCP”), good laboratory practice (“GLP”) and 
pharmacovigilance (“PhV”)  
• Implementing the EU telematics programme (aiming to promote synergy 
between different IT systems and databases both on national and European 
level) 
• Promoting innovation (for example through the guidelines and scientific advice 
EMA provides, in consultation with interested parties) 
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It is important to note that the EMA does not have any legislative power (Greer et al. 
2014). It falls under the competence of the Commission Unit D5: “Medicinal products - 
authorisations, European Medicines Agency” (European Commission 2015b). However, 
the EMA does impact health policy through the scientific advice, guidelines and other 
documents it provides. 
 
The agency structure interlinks with several bodies such as national authorities 
regulating medicinal products and the Commission (Cini and Pérez-Solórzano Borragán 
2010; European Medicines Agency 2014). In addition, EMA involves stakeholders in 
various ways, such as through consultations for new guidance, or recently more 
increasingly through stakeholder platform meetings bringing together various 
stakeholders in a transparent manner (European Medicines Agency 2013). 
 
2.1.5 Interest Groups 
 
Interest groups that could potentially be affected by certain EU policies or legislation 
can try to make the perspective they represent be heard by the institutions involved in 
the decision-making structure (Wahlroos 2003; Cini and Pérez-Solórzano Borragán 
2010). In addition to reacting to legislation or policy proposals for example through a 
consultation procedure, interest groups can also proactively advocate for a cause and try 
to bring it on the decision-making agenda. 
 
A myriad of interest groups operate at European level in order to advocate for the 
interests they represent and they perform a substantial role in the European decision-
making process in making it more informed, transparent and democratic (Cini and 
Pérez-Solórzano Borragán 2010; Greer et al. 2014; European Union 2014). In order to 
balance the work of the well-funded interest groups, the Commission also funds interest 
groups that would not be self-sustainable otherwise.  
 
Interest groups actively advocating on European level are expected to register on a 
voluntary “Transparency Register”, jointly operated by the Commission and the 
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Parliament (European Commission 2015d). Interest groups listed in this register related 
to the pharmaceutical sector include for example: 
• Associations representing pharmaceutical professions and sectors, such as the 
associations representing community pharmacies (PGEU, Pharmaceutical Group 
of the European Union), hospital pharmacists (EAHP, European Association of 
Hospital Pharmacists) and pharmaceutical wholesalers (GIRP, the European 
Association of Pharmaceutical Full-line Wholesalers) 
• Trade associations like the associations representing self-medication industry 
(AESGP, the Association of the European Self-Medication Industry), research-
based pharmaceutical industry (EFPIA, European Federation of Pharmaceutical 
Industries and Associations) and generic pharmaceutical industry (EGA, 
European Generic and Biosimilar medicines Association) 
• Associations representing academia, such as the associations representing 
faculties of pharmacy (EAFP, European Association of Faculties of Pharmacy) 
and pharmaceutical students (EPSA, European Pharmaceutical Students’ 
Association) 
• Groups with more general health-related interests such as the European Public 
Health Alliance (EPHA), associations related to other healthcare professions and 
patient organisations 
 
It is also important to remember that issues related to a certain sector will also concern 
interest groups of another sector, so the arguments brought forward through this 
interface will in most issues be very varied.  
 
2.2 Decision-making process at the EU level 
 
Figure 1 illustrates in a simplified manner the core EU decision-making process. First 
the European Council sets the strategic direction of the European Union and decides on 
priorities via the heads of Member States (Borchardt 2010; Cini and Pérez-Solórzano 
Borragán 2010; European Union, 2014; Greer et al. 2014). Under this mandate the 
Commission prepares European legislation, which is then adopted by the Council and 
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the European Parliament. In most cases this takes place through the ordinary legislative 
procedure (also called “co-decision”), which is described in detail in section 2.2.1 
 
A request for the Commission to prepare new legislation or revise existing legislation 
can come from the Council, the Parliament, the Commission itself or EU citizens via the 
European citizens’ initiative (requires the support of 1 million EU nationals from at 
least a fourth of the EU Member States) (Borchardt 2010; Cini and Pérez-Solórzano 
Borragán 2010; European Union, 2014; Greer et al. 2014). 
 
Figure 1 The EU core decision-making process, simplified version 
 
However, it is important to note that decision-making does not take place in a vacuum, 
but in interaction with various other bodies. Figure 2 depicts some of the important 
actors around that process such as the Courts of the European Union, EU’s specialised 
agencies as well as interest groups, which all interact with the decision making bodies. 
Any part of the decision making process is subject to information and influence from 
outside, which can be seen as a positive issue in terms of informing the process, but has 
also been criticised for not being always transparent (Cini and Pérez-Solórzano 
Borragán 2010). 
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2.2.1 Ordinary legislative procedure 
 
The three main decision-making bodies in EU legislation are the Commission, the 
Council and the Parliament. What takes place in most cases to pass European Union 
legislation is something called the ordinary legislative procedure (also known as “co-
decision”), meaning that once the Commission has produced draft legislation, the 
Council and the Parliament both need to agree on it in order for the legislation to pass 
(Borchardt 2010; Cini and Pérez-Solórzano Borragán 2010; European Union, 2014; 
Greer et al. 2014). This is described in detail in Figure 3. 
 
The process starting from drafting legislation to it being passed on EU level can last 
several years (Cini and Pérez-Solórzano Borragán 2010). This is because the 
preparation takes a long time and also because the process itself is not linear, but rather 
circular: the Council and Parliament rarely accept draft legislation as it is, but propose 
amendments, which then need to be assessed and the drafts adjusted. 
Figure 2 The EU core decision-making process and some 
important actors interacting with it, simplified version 
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Figure 3 The ordinary legislative procedure pictured in detail (Source: European Union 2014) 
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2.2.2 Hierarchy between different types of legislation 
 
European Union legislation has a certain “hierarchy” in terms of order of interpretation 
as well as legal strength or effectiveness. One visual interpretation of this is depicted in 
Figure 4, representing the legal hierarchy and interaction when it comes to issues 
falling under EU competence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4 Legal order and interaction in the EU 
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Primary legislation 
 
Highest in the diagram is so called “Primary legislation” referring to the Union Treaties, 
the most important of which to this research are the Treaty on European Union (TEU) 
and Treaty on the Functioning of the European Union (TFEU). The treaties have been 
agreed and signed by all Member States and define what is and is not a competence of 
the European Union, as well as to what extent (Borchardt 2010; European Union 2014). 
This means that the Member States have agreed to give part of their sovereignty away to 
the supranational entity of the European Union in certain issues, which is reflected in 
the principle of autonomy of the EU legal order (see 2.3.1) and means that the 
European Union is a union based on the rule of law. The EU can only develop 
legislation on competences mentioned in the treaties and therefore they are the basis for 
all legislative proposals made by the European Commission as well as any 
interpretation made by the Court of Justice of the European Union (“legal basis”). 
 
The treaties can be divided into two main categories: founding treaties and amending 
treaties. The latest founding treaty is the Treaty on European Union, also known as the 
“Maastricht Treaty”, signed in 1992 and came into force in 1993 (Borchardt 2010; 
European Union 2014). The Maastricht Treaty established the European Union and was 
later amended later by the Treaty of Amsterdam (signed in 1997 and came into force in 
1999), the Treaty of Nice (signed in 2001 and came into force in 2003) and the Treaty 
of Lisbon (signed in 2007 and came into force 2009). The treaties are also amended 
when new Member States join the EU, all amendments and changes are incorporated 
into “consolidated” versions of the Treaties. 
 
Note: this study refers to the consolidated versions of the European Treaties (Official 
Journal of the European Union C 326 of 26 October 2012), however some of the Court 
of Justice cases included in this study commenced before the Treaty of Lisbon came into 
force (usually cases commence much earlier than when the first public sections of the 
proceedings take place) and therefore refer to previous article numbering. In such cases 
a correspondence to current treaty numbering is provided. 
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Secondary legislation 
 
Secondary legislation refers to legislation that is derived from the Union Treaties and 
developed by the European Union decision-making bodies (Borchardt 2010).  
 
Main types of secondary legislation are, in order of descending level of strength, the 
following (Borchardt 2010; European Union 2014; Greer et al. 2014): 
 
• Regulations 
Regulations are directly applicable and binding to Member States and do not 
need to be transposed into national legislation. However, national legislation 
might require to be changed in order not to contradict a regulation. An example 
of an important regulation affecting health would be the regulation on 
coordination of social security systems. 
 
• Directives 
Directives specify a particular objective and it is then up to Member States to 
define how this should be done, directives are therefore transposed into national 
legislation. They can be binding to all Member States or limited to a group of 
Member States. An example of a directive with direct influence on health is the 
“Directive on the Application of Patients’ Rights in Cross Border Healthcare”. 
 
• Decisions 
Decisions are binding and may be addressed to Member States, groups or 
individuals. They can have various functions including ratifying reports of the 
Commission, such as the European Semester, which forms a part of EU fiscal 
governance and could have an influence on national health budgets. 
 
In addition to the above-mentioned, the Commission may be assigned power to develop 
delegated acts and implementing acts, replacing what was previously called 
“comitology”. They are non-legislative instruments but still binding in nature and help 
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define or amend EU legislation, which could be subject to change especially in terms of 
more technical aspects (Borchardt 2010; Greer et al. 2014). 
 
2.2.3 “Hard law” versus “Soft law” 
 
In addition to legally binding tools the EU institutions possess a broad palette of other 
instruments to influence policies and action on national and European level (Borchardt 
2010; European Union 2014; Greer et al. 2014). These tools as examples of “soft law” 
in contrast to “hard law” such as treaties and regulations describe an essential part of the 
processes through with the European Union works in order to reach its objectives on a 
more concrete level. 
 
Recommendations are an example of legal acts that call for action but are not binding 
(Borchardt 2010; European Union 2014; Greer et al. 2014). The institutions may also 
issue resolutions, adopt declarative documents or draw up action programmes that are 
not legally binding, but have political significance and impact on the EU agenda. 
Declarative documents typical to the EU institutions include Parliament Opinions, 
Council Conclusions and Commission Communications. 
 
2.2.4 Role of interest groups in EU decision-making 
 
Any step of the decision making processes described previously from setting the 
strategy on Council and Commission level to preparing legal texts, the readings by 
Parliament and Council, voting on legislation as well as its implementation (and 
potential amendments) are all subject to influence from interest groups (Cini and Pérez-
Solórzano Borragán 2010).  
 
This can be more transparent either in the form of the bodies, such as the Commission, 
opening a consultation for interest groups (usually submissions are also made public) or 
interest groups issuing public statements, opinions, press releases and open letters to 
make their opinion and justification behind it known (Cini and Pérez-Solórzano 
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Borragán 2010). This is combined with a less transparent aspect of interest group 
influence taking place for example via bilateral meetings and personal relationships.  
 
Even though there are several negative connotations linked to interest group advocacy 
(or “lobbying”), the importance of having the possibility to hear interest group opinions 
has been clearly acknowledged, as it would be impossible for decision makers to find 
out all the information on potential impacts of legislation being discussed and 
backgrounds to different sectors and population subgroups otherwise (Cini and Pérez-
Solórzano Borragán 2010; Greer et al. 2014). In order to promote a balanced input from 
different interest groups, the European Union provides funding for groups that are 
financially not as well supported as others. 
 
2.3. Interaction between EU and national legislation 
 
2.3.1 Basic principles dictating interaction between EU and national legislation 
 
The interaction between EU and national legislation is complex and follows several 
basic principles such as those elaborated in the following text (Borchardt 2010, 
European Union 2014): 
 
• Autonomy of the EU legal order 
This principle ensures that EU law will be implemented in the same way in all of 
its Member States. By signing the Treaty Member States have agreed to give 
away part of their sovereignty to the supranational union law, which is binding 
on the Member States, their national courts and their citizens. The consequence 
is that Member States must follow what has been agreed in EU legislation in all 
levels of government: executive, legislature and judiciary. In other words it does 
not only apply to the creation of new legislation but also the work of the national 
courts and so forth. The degree to which EU legislation should be adopted 
depends on the type of EU legislation (see section 2.2.2).  
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• Sincere cooperation 
The principle of sincere cooperation is enshrined in the Treaty (Article 4(3) 
TEU) and relates to the idea of the EU and its Member States working together 
to reach the aims agreed in the EU Treaties on all levels of legislation and 
jurisprudence, European and national. EU legislation alone cannot enable to 
obtain all the agreed aims, and therefore, it is up to Member States to 
complement this by setting national legislation based on the same common 
objectives. EU and national legislation are therefore interdependent and require 
shared effort to work as an effective Union. 
 
• Direct applicability 
What follows from the principle of direct applicability is that European Union 
law does not only affect its institutions or its Member States, but also EU 
citizens directly, meaning that they are allowed to appeal to those rights. The 
landmark case setting this principle was that of Van Gend & Loos (Case 26/62 
1963), where the Court of Justice ruled that individuals may also invoke the 
Article 12 of the EEC Treaty, against the advice of several Member States and 
the opinion of the Advocate General of the case. 
 
• Primacy of Union law over national law 
Following from the autonomy of EU legal order it is now accepted that if 
national legislation contradicts EU legislation, EU legislation must be followed. 
This means that contradicting national law must cease to be implemented and 
any new national legislation must be in accordance with EU legislation. As this 
is not directly stated in any primary or secondary EU legislation, it was through 
the seminal case of Costa v ENEL (Case 6/64 1964) that the Court of Justice 
ruled that: “It follows from all these observations that the law stemming from 
the Treaty, an independent source of law, could not, because of its special and 
original nature, be overridden by domestic legal provisions, however framed, 
without being deprived of its character as Community law and without the legal 
basis of the Community itself being called into question.” 
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• Interpretation of national law in line with union law 
Following from the principles of autonomy and primacy, Member States are also 
obliged to interpret national law in line with EU law, the principle that was 
established by the Court of Justice via the case of Von Colson and Kamann 
(Case 14/83 1984). Not only are the national courts obliged to follow EU 
legislation, but also in cases of uncertainty to refer questions regarding its 
interpretation or implementation to the Court of Justice, who has the ultimate 
power to interpret European Union law, through the preliminary ruling 
procedure (Article 267 of the TFEU, ex 234 TEC). 
 
• Subsidiarity  
The subsidiarity principle basically outlines that what can be done on national 
level should not be done on EU-level, so only for issues where it will bring 
additional benefit should there exist supranational legislation.  
 
As can be seen, the interaction between national and EU legislation is an intricate affair 
and all the principles guiding it (despite any initial resistance from Member States) are 
crucial in order for the EU to function and its objectives to be achieved. 
 
2.3.2 Role of the Court of Justice of the European Union 
 
There are multiple bodies within the EU structure whose task is to ensure that what 
takes place on EU-level (within the EU bodies but also to some extent on Member State 
level) is done in accordance to what has been agreed by the Member States. For 
example, in terms of EU budget and finances it is the European Court of Auditors and in 
terms of legislation they are the courts of the European Union (Court of Justice of the 
European Union 2014; European Union 2014). 
 
The European Union has several courts, but the one of interest to this study is the Court 
of Justice of the European Union (“CJEU”). 
 
 21 
The purpose of the Court is to ensure that European legislation is interpreted and 
applied consistently across all Member States (Court of Justice of the European Union 
2014; European Union 2014). It plays a crucial role in resolving contradictions between 
national and EU legislation through its judgments and establishing precedence for future 
interpretation, especially in cases where EU legislation is not clear or lacking.  
 
The Court consists of two main bodies: The Court of Justice and the General Court.  
Both include 28 judges, one from each EU Member State, representing all the national 
legal systems. Both bodies also elect a president among their 28 judges. In addition, the 
Court of Justice has also nine Advocates General, who prepare reasoned opinions to 
present on the cases brought to the Court. The Court of Justice acts as the highest 
instance in EU legal order (Article 253 TFEU, ex 223 TEC). 
 
2.3.2.1  Court of Justice procedure 
 
Depending on the complexity and potential impact of the case at hand a different 
amount of judges will be assigned to the case (Court of Justice of the European Union 
2014; European Union 2014). Most cases are heard by Chambers of five judges (almost 
60% of the Court of Justice cases) or Chambers of three judges (approximately 80% of 
the General Court cases). In cases of high importance or complexity a Grand Chamber 
of thirteen judges or a full Chamber (full court) could also meet. 
 
The general court procedure follows the order described in Figure 5 (Court of Justice of 
the European Union 2014). 
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The court rules on four main types of proceedings: 
• The preliminary ruling 
• Infringement proceedings 
• Proceedings for annulment 
• Proceedings for failure to act 
 
Out of these four main types the first two are of relevance to this study and will be 
addressed in further detail in the following sections.  
 
Figure 5 The general procedure before the Court of Justice  
(source: Court of Justice of the European Union 2014) 
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2.3.2.2  Preliminary ruling  
 
The preliminary ruling procedure (Article 267 TFEU, ex Article 234 TEC) is a 
procedure national courts may (and in some cases must) invoke in cases where they are 
in doubt regarding the interpretation or validity of EU legislation, as they are obliged to 
follow EU law in their work (Court of Justice of the European Union 2014; European 
Union 2014). The outcome of the procedure is a “preliminary ruling” which is binding 
in nature. The reference for preliminary ruling procedure must be based on an on-going 
case on national level and cannot be based on a merely theoretical issue (Court of 
Justice of the European Union 2012). 
 
2.3.2.3  Infringement proceedings 
 
If it is suspected that a Member State is not fulfilling its obligations according to EU 
law (either not adopting or transposing EU legislation or alternatively maintaining 
national legislation that is in contradiction with current EU law), infringement 
proceedings may be initiated against that Member State (Court of Justice of the 
European Union 2014; European Union 2014).  
 
In most cases it is the Commission initiating such proceedings, being the body in charge 
of ensuring the implementation of EU legislation, but it could also be another Member 
State (Court of Justice of the European Union 2014; European Union 2014). If the 
Member State is deemed to be at fault according to the judgment, the Court may apply 
fines if the situation is not corrected within appropriate timing. 
 
2.3.2.4  Applicability of EU case law 
 
Cases brought to the Court of Justice can be resolved as judgments,  
Judgments of the CJEU define how law is interpreted in the future by creating 
precedents and subsequent case-law and have legal applicability to all future similar 
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cases whereas orders4 follow what has already been defined by preceding judgments. 
Case-law supplements primary and secondary EU legislation but also constitutional and 
statutory law on national level, at least until it is overridden by new case-law, EU 
legislation or a treaty change (Borchardt 2010; Greer et al. 2014). 
 
The judgment following the Costa v ENEL case has cemented the superseding role of 
EU law over national legislation, and therefore, the role of the Court, who has the 
ultimate power to interpret EU law. The remit of the Court has been defined as judicial, 
but it has been criticised as to whether it is in fact acting outside this scope (e.g. 
Wasserfallen 2010).  
 
For example, in terms of references for preliminary ruling, it is up to national courts to 
determine when such a procedure is needed and for the Court to assess, whether the 
questions are admissible in terms of its remit. Several legal academics and even 
Advocates General of the Court itself have questioned whether the Court has deemed 
admissible cases that would in fact not necessarily be so (for example opinion of 
Advocate General in joined Cases C‐159/12, C‐160/12 and C‐161/12, Venturini and 
others 5.9.2013).  
 
The amount of cases handled by the Court has steadily risen, for example in 1990 the 
Court of Justice gave 193 judgments/opinions whereas in 2014 the respective number 
was 416 (Court of Justice of the European Union 2015) and therefore its impact and role 
have only become stronger. The Court of Justice has indeed been referred to as one of 
the most powerful courts in the world (Conant 2002).  
 
 
  
                                                
4 Orders involving a judicial determination 
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3 AT THE INTERFACE BETWEEN PUBLIC HEALTH AND  
            INTERNAL MARKET 
 
3.1 Healthcare in the EU – does there exist a European health policy? 
 
3.1.1 Constitutional asymmetry and the healthcare dilemma 
 
Constitutional asymmetry refers to the fact that the EU has stronger mandate and 
competence to address certain topics than others (Brooks 2012; Greer et al. 2014). The 
Treaty of the European Union clearly states areas of competence where the EU has full 
mandate to work (exclusive competence), such as in competition, trade, customs, 
monetary policy for the Euro area and the conservation of fish (Article 3 TFEU).  
 
In addition, there are areas where the EU and Member States share competence, 
meaning that the role of the EU is more limited and only applicable when it will bring 
more added value than addressing the topic on national level (Article 4 TFEU; 
European Union 2014; Greer et al. 2014). Areas of shared competences include for 
example agriculture, internal market, transport, environment and consumer protection 
as well as “common safety concerns in public health matters”.  
 
Then there are also issues that Member States have expressly wished to keep as a 
national competence. In terms of “protection and improvement of human health” it is 
stated in Article 6 TFEU that the “Union shall have competence to carry out actions to 
support, coordinate or supplement actions of the Member States”. As the Treaties 
should be the basis for any legislation drafted by the Commission, it is not possible to 
propose EU legislation on policy areas that are not included in the Treaties (European 
Union 2014). 
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3.1.2 History of healthcare in the EU legislation 
 
Even though Member States have agreed on health and its protection being one of the 
most important common primary interests (Article 9 TFEU and Article 168 TFEU ex 
Article 152 TEC), they have not been willing to give up their sovereignty on national 
health issues, especially regarding health systems and their financial aspects (Greer et 
al. 2014). Therefore, it was only in 1992 that an article in the Treaty was introduced on 
health (Article 168 TFEU ex Article 152 TEC), dealing namely with public health.  
 
However, health has been part of other Treaty articles since much earlier. For example, 
already the founding treaties created in the 1950s included provisions on health, related 
to issues such as access to healthcare for workers moving between EU Member States, 
coordination of social security systems and a substantial role in bettering health in areas 
like environment or health and safety at work (Greer et al. 2014).  
 
In addition to health-related Treaty provisions, the principle of “Health in All Policies” 
or “HiAP” was introduced at the same time as the article on health, which implies that 
health considerations should always be taken into account when drafting new legislation 
(European Public Health Alliance 2013; Greer et al. 2014). 
 
The implementation of the health in all policies principle was first monitored through 
regular Commission reports, which then became less frequent and comprehensive and 
were finally replaced by the health impact assessment (Greer et al. 2014). The 
Commission was therefore required to ensure that the potential impacts of new 
legislation on health were evaluated before it could be passed.  
 
However, as similar “integration clauses” were applied to other areas than health, such 
as environment, animal welfare, development cooperation, culture, regional policy and 
consumer protection, all the different impact assessments were merged into one joint 
impact assessment. The validity of these impact assessments has been criticised both 
internally by Commission staff as well as externally (Evaluation Partnership 2007; 
Koivusalo 2010; Smith et al. 2010). Ultimately it is also very challenging to predict 
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impact of legislation as it will often be incorporated or transposed either a bit differently 
by each Member State or at least into different legal frameworks and societies. 
 
Complementing EU legislation (both primary and secondary), there is a large body of 
case-law that has played a crucial role in determining interpretation of legislation in 
health related issues such as for cross-border healthcare, though the judgments of the 
Court of Justice (Brooks 2012; Greer et al. 2014). This aspect will be further developed 
in this research. 
 
Lastly, there are also areas that have not had any official health related competence and 
yet have resulted with very concrete impacts on it, a more recent example being the 
increased EU fiscal governance (Greer et al. 2014). 
 
3.1.3 Health in current EU legislation and policy 
 
Health is a particularly tricky area, as in itself it is not an official EU competence 
(TFEU; Brooks 2014; Greer et al. 2014). This stems from the fact that health systems 
are structured very differently in each Member State, and therefore, the Member States 
have wanted to keep control over their own systems.  
 
The only area where health as the main objective has been agreed on at Treaty level is 
that of public health, mainly in the form of coordination and support to Member States 
(Article 168 TFEU, ex Article 152 TEC). Reflecting this, the Directorate-General for 
Health and Food Safety (SANTE) in fact has mainly competence over issues of public 
health. 
 
However, even though Article 168 is the only one exclusively related to health, several 
of the other ones also refer to health as mentioned previously.  
 
For example the Treaty article on environment states the following (Article 191 TFEU, 
ex Article 174 TEC): 
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Union policy on the environment shall contribute to pursuit of the following objectives: 
– preserving, protecting and improving the quality of the environment, 
– protecting human health, 
– prudent and rational utilisation of natural resources, 
– promoting measures at international level to deal with regional or world- wide 
environmental problems, and in particular combating climate change. 
 
What follows from this is that health is impacted by legislation and action taking place 
in areas not explicitly linked to health and therefore not involving health policy people 
(European Public Health Alliance 2013; Greer et al. 2014). The Commission DG: s 
develop legislation based on the agreed competences, promoting agendas related to their 
specific portfolios. However these have significant impact on health. For example the 
Directorate-General for Research and Innovation (DG RTD) is responsible for the EU 
research budget, often providing support to biomedical and other health-related research 
and therefore influencing what areas of healthcare are developed further, the 
Directorate-General for Communication Networks, Content and Technology (DG 
CNECT) on the other hand influences greatly in the areas of health information 
technology and e-health and the Directorate-General for Regional and urban Policy (DG 
REGIO), which provides significant financing to health infrastructure through 
managing structural funds. 
 
In addition to internal, also external issues in the remit of the EU affect health, such as 
neighbourhood policy and trade agreements (Greer et al. 2014). The Directorate-
General for Trade (DG TRADE) for example has an important role in negotiating trade 
agreements for the EU, which often contain provisions on regulation of issues tightly 
related to health, such as alcohol, tobacco, food, medical devices and pharmaceuticals. 
 
What all of this amounts to is that in fact, majority of the influence of decisions 
affecting health, come through actions driven by other agendas. 
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3.2 At the interphase between internal market and public health 
 
As it has been demonstrated, there are several areas the European Union has been 
mandated to work on in order to further goals and policies agreed by its Member States 
and sometimes these goals and policies are in contradiction. One of the areas of 
contradiction is the interface between internal market and public health, studied by e.g. 
Wahlroos (2003), Baeten and Palm (2011) and others.   
 
3.2.1 Defining public health 
 
Public health is defined, organised and implemented very differently in EU Member 
States, which adds to the complexity of creating or implementing any supranational 
legislation or action in the area (Greer and Kurzer 2013).  
 
Greer in Greer and Kurzer 2013 has defined public health (policy) as follows: 
Public health policy is that range of policies that contribute to such an end – from 
injury prevention to anti-smoking campaigns, to health systems strengthening, to 
microbiological research. - - In other words, public health is affected by almost every 
policy in government, and almost every policy in government could potentially be seen 
as more or less successful public health policy. 
 
He goes on to state: “The problem of integrating public health into the thinking of other 
policymakers, aka ‘Health in all policies,’ has scarcely been solved”, so regardless of 
the fact that public health is present in such a variety of forms or precisely because of 
this complexity, it is effectively challenging to take it into account in every aspect. Not 
in the least because it should still be mostly a Member State competence.  
 
An attempt to address this has been made by requiring the assessment of impacts on 
public health within the impact assessment undertaken for new EU legislation (Greer et 
al. 2014), however these impact assessments have received widespread criticism 
regarding their validity.  
 
 30 
3.2.2 Defining internal market 
 
In the context of the European Union, the concept of internal market is crystallised in 
the “fundamental freedoms” enshrined in the union treaties. The fundamental freedoms 
consist of freedom of establishment, freedom to provide services and free movement of 
good, services and workers (Treaty on the Functioning of the European Union; 
Borchardt 2010). As internal market forms such an essential part of the aims behind the 
EU, the Commission has been given a strong mandate to facilitate its realisation within 
the union, and has done so through various initiatives, such as its agenda to de-regulate 
the liberal professions (see 5.2.3). 
 
3.2.3 Dynamics between the two agendas 
 
As mentioned, one of the driving ideologies behind the whole European Union is that of 
the fundamental freedoms. On the other hand, it is also clearly expressed that the 
protection of public health should take highest priority, which has also been reinforced 
by the “health in all policies” approach. 
 
When internal market and public health interests are in line, strong policies can be seen 
to emerge, such as in the case of cross-border healthcare (Brooks 2012; European 
Public Health Alliance 2013; Greer et al. 2014). However, it becomes problematic when 
the interests are in contradiction, as different bodies have different backgrounds and 
interpretations against which they will assess the balance between internal market and 
public health needs. 
 
An example of this is the case study of community pharmacy regulation, where high 
restrictions on national level are in direct contradiction with the principles of internal 
market and competition, having been justified by public health benefits. This is also 
where the role of the Court of Justice has been perceived as key in facilitating 
interpretation related to EU legislation and its dynamics with national regulation. 
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4 INDICATION OF A STRENGTHENING EUROPEAN  
            HEALTHCARE AGENDA 
 
4.1 Theoretical Framework: European integration and the spillover thesis 
 
4.1.1 Theories behind European integration 
 
Several theories have been developed to explain European integration, the main 
dichotomy being between neo-functionalism, which focuses on supranational interest 
as a driving force for integration and intergovernmentalism, which insists that 
integration (or rather cooperation) takes place in order to serve national interests, which 
are the true driving force behind it (Cini and Pérez-Solórzano Borragán 2010). Neo-
functionalism and more precisely the spillover thesis were chosen as the theoretical 
framework for this study and are further elaborated on in the next chapter. 
 
4.1.2 Neo-functionalism and spillover 
 
Neo-functionalism is one of the core theories used to explain European integration, 
developed in the 1950’s (Haas 1958; Cini and Pérez-Solórzano Borragán 2010; Brooks 
2012). It suggests that supranational interest defines and drives integration in systems 
like the European Union. Among the key concepts of neo-functionalism are the 
spillover thesis, the elite socialization thesis and that on supranational interest 
groups. 
 
Perhaps the most known concept is the spillover thesis, which proposes that in order to 
fulfil goals of political cooperation, new goals will be created extending the scope and 
intensity of cooperation beyond the original intent (Haas 1958; Lindberg 1963; Hooghe 
and Marks 2007). 
 
This is exemplified by the case of free movement of professionals (original goal) within 
the European Union, which could be seen as to have lead to initiatives in harmonising 
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education in Member States (spillover to another sector) to enable recognition of those 
professionals to be able to practice their profession in other countries (Cini and Pérez-
Solórzano Borragán 2010). This would be regarded as an example of functional 
spillover, which suggests that cooperation in one area creates pressure for cooperation 
in other areas, which might have not been originally intended.  
 
In addition, the spillover thesis introduces the concepts of political spillover and 
cultivated spillover (Nye 1971; Tranholm-Mikkelsen 1991; Rosamond 2005; 
Moravcsik 2005; Niemann 2006). Political spillover refers to situations where actors 
(national or European level) promote integration in order to attain some other goal. The 
thesis proposes for example that actors like national political elites or interest groups 
could perceive that their political agenda might have better success addressed on a 
European rather than national level and therefore argue for political integration. In this 
case the process is perceived as more deliberate, but still cooperation is not the ultimate 
purpose but rather a means for a political agenda. 
 
Cultivated spillover on the other hand describes the role of supranational bodies in 
pushing for integration during intergovernmental negotiation (Tranholm-Mikkelsen 
1991; Niemann 2006). An example of this could be when during negotiations with 
Member States, the Commission would favour arguments pro integration over those 
promoting national interests. Another example would be facilitating “package deals”, 
which include several different areas of interest to different Member States being put 
together to be adopted as one package, in order to defend their own particular interest 
(Lindberg and Scheingold 1970).  
 
4.2 Indication of spillover in relation to health in EU policy 
 
It has been argued that since the “revolution in European law and governance” in the 
early 1990s, in other words following the introduction of new modes of governance, the 
role of bodies such as the European Court of Justice have grown in health policy as 
opposed to previously when health related legislation was created through the 
“Traditional” or “Community” method (Brooks 2012). 
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Several sources describe the role of the Court of Justice as a kind of precursor to hard 
law through the judgments it generates or as a mechanism to ensure that hard law is 
being implemented in the Member States (Greer and Vanhercke 2010; Brooks 2012). 
 
Brooks (2012) demonstrates through the case example of the European “Directive on 
the Application of Patients’ Rights in Cross Border Healthcare” how the Court of 
Justice through judgments on patient mobility cases, and a subsequent body of case law 
essentially defined how further legislation was developed. Indeed, this was reflected in 
the resulting legal text (also e.g. Greer et al. 2014). 
 
This could be seen as a classical example of spillover, as the role of the CJEU is to 
defend the EU treaties and any other existing EU legislation, but when they have to be 
applied to issues that relate to healthcare, they will obviously have an influence on it as 
well and might require further legislation to be created. 
 
Those who do not support this theoretical approach have criticised it for giving the 
Court of Justice too big a role in the EU policy processes and believe that the CJEU 
would not be a central institution in influencing emerging legislation (Brooks 2012). It 
has also been suggested that the directions it takes would reflect the interests of the most 
influential Member States. 
 
 
5 FOCUS ON COMMUNITY PHARMACY REGULATION IN THE EU 
 
5.1 Legal aspects to community pharmacy regulation in EU 
 
This chapter will focus on aspects of EU legislation relevant to the establishment, 
ownership and distribution of community pharmacies. 
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5.1.1 Primary legislation (Treaty level) 
 
Community pharmacies, like other establishments, fall within the remit of the basic 
freedoms enshrined in the EU Treaties, including the freedom of establishment (right to 
“take up and pursue activities as self-employed persons and to set up and manage 
undertakings”, Article 49 TFEU), freedom to provide services, free movement of 
workers, capital and goods (Articles 34, 45, 49 and 57 Treaty on the Functioning of the 
European Union, Borchardt 2010). 
 
Being at the interface between public health (providing health services) and internal 
market (maintaining a profit-making business), community pharmacy is also affected by 
Treaty Provisions related to public health. The Article specifically dedicated to public 
health mainly states that public health is a shared competence between the EU and its 
Member States, primarily dictated on national level (Article 168 TFEU, ex Article 152 
TEC).  
 
However, as public health is addressed in several other Articles of the Treaty, this is 
also the case for the Articles on Internal Market, which include provisions stating that 
restrictions on the fundamental freedom may be justified with reasons of overriding 
general interest, such as public health (Article 52 TFEU, ex Article 46 TEC). 
 
5.1.2 Secondary legislation 
 
The most relevant directive to community pharmacy is Directive 2005/36/EC (replacing 
Council Directive 85/432/EEC of 16 September 1985 and Council Directive 
85/433/EEC of September 1985), which elaborates on tasks of the regulated healthcare 
professions, such as pharmacists as well as the mutual recognition of their professional 
qualifications. 
 
The Directive specifically states: This Directive does not coordinate all the conditions 
for access to activities in the field of pharmacy and the pursuit of these activities. In 
particular, the geographical distribution of pharmacies and the monopoly for 
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dispensing medicines should remain a matter for the Member States. This Directive 
leaves unchanged the legislative, regulatory and administrative provisions of the 
Member States forbidding companies from pursuing certain pharmacists’ activities or 
subjecting the pursuit of such activities to certain conditions. 
 
Therefore it is up to the member state to decide on matters such as restrictions on 
pharmacies/pharmaceuticals, as long as this is in compliance with the Treaty, including 
provisions related to freedom of establishment. 
 
5.1.3 National legislation 
 
The level of regulation of the pharmaceutical sector varies a lot across European 
countries (for example Mossialos and Mrazek 2003; Vogler et al. 2014). Commonly 
used examples of highly regulated countries in literature include Spain, Austria, France 
and Finland, which all restrict pharmacy ownership to pharmacists as well as have 
establishment criteria in addition to restricting medicines sales to pharmacies (for 
example Mossialos and Mrazek 2003; Anell 2005; Lluch 2009; Vogler et al. 2014). 
Respectively, widely used examples of highly liberalised countries include for example 
Ireland, Norway, The Netherlands and Iceland, which have no restrictions on the issues 
mentioned in relation to the previous four countries.  
 
Based on materials provided by the PGEU5 (unpublished, 2015) and supportive 
literature, European countries can be divided according to different aspects and levels of 
liberalisation of the pharmacy sector as described in Table 1. 
 
 
                                                
5 Collected member association inputs, have not been validated in any other way 
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Table 1 Level and type of regulation of the community pharmacy sector in different European 
countries  
Country 
Ownership 
limited to 
pharmacists 
(14/32) 
Ownership 
limitations for 
chains (2/32) 
Liberalised 
ownership 
(16/32) 
Establishment 
criteria (18/32) 
OTC-sale limited 
to pharmacies 
(17/32)  
Ownership regulated      
1. Austria* X   X X 
2. Bulgaria  X    
3. Cyprus X    X 
4. Denmark X   X  
5. Finland* X   X X 
6. France* X   X X 
7. Germany X    X 
8. Greece (*) X   X (X) 
9. Hungary* X   X X 
10. Italy X   X  
11. Latvia* X   X X 
12. Luxembourg* X   X X 
13. Portugal  X  X  
14. Slovenia* X   X X 
15. Spain* X   X X 
16. Turkey* X   X X 
Ownership liberalised      
17. Belgium   X X X 
18. Bosnia&Herzegovina**   X   
19. Croatia   X X X 
20. Czech Republic**   X   
21. Ireland**   X   
22. Lithuania   X  X 
23. Macedonia(FYROM)**   X   
24. Malta   X X X 
25. Netherlands**   X   
26. Norway**   X   
27. Poland**   X   
28. Romania   X X  
29. Serbia**   X   
30. Slovakia   X  X 
31. Sweden**   X   
32. UK   X X  
* = highly regulated community pharmacy sector, ** = highly liberal community 
pharmacy sector 
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As can be seen from Table 1, the level of regulation or liberalisation among the 32 
European countries included is very heterogeneous: a little below half of the countries 
(~ 44%) limit pharmacy ownership to pharmacists only and half of the countries (50%) 
have completely liberalised pharmacy ownership, the rest (~ 6%) maintain ownership 
limitations for chains. Additionally, more than half of the countries have implemented 
some sort of establishment criteria (~ 56%) and/or limited the sale of OTC medicine to 
pharmacies (~ 53%). 
 
According to information collected, the most highly regulated countries (ownership 
limited to pharmacists, establishment criteria in place and limitation of sales of OTC 
medicines to pharmacies) include: Austria, Finland, France, Hungary, Latvia, 
Luxembourg, Slovenia, Spain and Turkey. The most liberal countries on the other hand 
(none of the previously mentioned areas regulated in the countries) include: Bosnia & 
Herzegovina, Czech Republic, Ireland, Macedonia (FYROM), the Netherlands, 
Norway, Poland, Serbia, Slovakia and Sweden. 
 
5.2 Community pharmacies at the interface between internal market and public health  
 
As described earlier, the community pharmacy sector is particularly fascinating due to 
being at the interface between sometimes competing internal market and public health 
interests. Therefore it is beneficial to examine some of the argumentation behind 
maintaining community pharmacy regulation or in contrary liberalising the sector, from 
the internal market versus public health perspective. To further expand on this, some of 
the existing literature on impacts or potential impacts was reviewed. The outcomes of 
this review along with a description of the political environment at the time of majority 
of the court cases are also addressed. Lastly, they are followed by a brief description of 
the resulting actions. 
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5.2.1 Arguments for and against liberalisation 
 
The community pharmacy sector has traditionally been relatively highly regulated in 
order to guarantee broad access to high quality pharmaceutical services for the 
population, in other words in order to protect public health needs of the population 
(Vogler et al. 2006).  
 
Typical examples of community pharmacy regulation on national level include 
controlling (Vogler et al. 2006): 
 
• Establishment of new pharmacies (often based on different criteria related to 
needs of the population) 
• Distribution of pharmacies 
• Ownership of pharmacies 
• Training of pharmacists and other pharmacy staff 
• Tasks of pharmacists (services that can be provided) 
• Products that can be distributed from a pharmacy / distribution of medicinal 
products 
 
The level of community pharmacy regulation varies across EU Member States from 
completely liberalised to highly regulated, as described in section 5.1.3.  
 
Since the concept of pharmaceutical care was coined by Hepler and Strand (1990) and 
more widely adopted as a core task of community pharmacists, it has been assumed as 
one of the fundamental aspects enabling pharmacies to protect and promote public 
health (FIP/WHO 2011) and is also clearly acknowledged in several of the opinions of 
the advocates general as well as consecutive judgments included in this study. For 
example, in the “Joint FIP/WHO guidelines on good pharmacy practice: standards for 
quality of pharmacy services” adopted by the International Pharmaceutical Federation 
(FIP) and the World Health Organization (WHO) in 2011, the aim of pharmacy practice 
is summarised as to "contribute to health improvement and to help patients with health 
problems to make the best use of their medicines." 
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Pharmacy practice is also divided into the following four key roles (FIP/WHO 2011): 
 
• Prepare, obtain, store, secure, distribute, administer, dispense and dispose of 
medical products 
• Provide effective medication therapy management 
• Maintain and improve professional performance 
• Contribute to improve effectiveness of the health-care system and public health 
 
However, several studies have indicated that the current level of pharmaceutical care, 
including for example patient counselling, offered at community pharmacies across 
Europe is not as high as expected and in fact still relatively limited (for example Van 
Mil and Schulz 2006; Hughes et al. 2010). Therefore in order to truly serve the purpose 
of obtaining a high level of pharmaceutical services, options such as regulating the 
services offered or better reimbursement of those services could be discussed. Once the 
best ways to improve the level of pharmaceutical service are found they should be 
compared to the alternative options currently discussed.  
 
EU case law has clearly stated that medicinal products are different from other goods 
due to their therapeutic effect and particular nature (for example, Case C-369/88 
Delattre [1991]), and therefore regulating how and who can administer them can have 
an effect on public health.  
 
Additionally, the Pharmaceutical Group of the European Union has for example issued 
a statement on why pharmacists are essential at community pharmacies in enabling the 
protection of public health, with unique knowledge, skills in supporting safe and 
appropriate medical treatment and an extensive educational background in the area, 
leading to a professional responsibility (Pharmaceutical Group of the European Union 
2009).  This statement was issued at the time when the Swedish government was 
discussing whether to reduce or abolish national requirements related to the 
involvement of pharmacists at community pharmacies, which PGEU expressed could be 
detrimental for public health. It has also been further supported by PGEU statistics 
showing that “58% of EU citizens can reach their nearest community pharmacy within 5 
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minutes” and “98% of EU citizens can reach their nearest community pharmacy within 
30 minutes” (PGEU 2015). 
 
Establishment rules, such as population based criteria or minimum distance are in 
general justified by public health benefits such as equal access to community 
pharmacies and pharmaceutical services (for example joined cases C-570/07 C-571/07 
Blanco Pérez and Chao Gómez as well as case C-367/12 Sokoll-Seebacher), from 
several of the cases included in this study it also seems that competition is perceived as 
a threat and has been speculated to potentially lead to deterioration of pharmaceutical 
services especially in cases where the pharmacy owner is not a pharmacist and 
potentially more inclined to push an employed pharmacist to prioritise economic 
benefits. Lastly, some of the argumentation used against liberalisation includes the 
threat of horizontal or vertical integration leading potentially to market dominance by 
big corporate bodies and product range limitations (for example Anell 2005). 
 
Argumentation for liberalisation include increase in competition resulting in lower costs 
of pharmaceuticals for patients as well as government, without compromising patient 
access – potentially even improving it through an increase in the number of pharmacies 
and other outlets for medicinal products. For example, according to Blöndal (2009) the 
aims of the deregulation activities taking place in Sweden were to “-- achieve efficiency 
gains, better accessibility for consumers, price pressure, and safe and appropriate use of 
medical products”. This is in line with the goal of creating an internal market in the 
European Union, enshrined in its Treaties, promoting freedom of establishment, free 
movement of capital, goods and people as well as removing barriers for competition.   
 
The Commission writes about the liberal professions (including pharmacy) as follows 
(European Commission 2015a): 
 
The liberal professions include lawyers, notaries, engineers, architects, doctors, 
dentists, accountants, and many others. They all require special training in the arts or 
sciences, and their activities are usually closely regulated by national governments or 
professional bodies. The services they provide are very important for European 
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businesses and consumers. The European Commission seeks to identify the main 
challenges professionals face and help create an environment where they can further 
develop their skills. 
 
It also identifies “reduction of the regulatory burden including the need for clearer and 
simpler rules governing professions” as one of the main challenges faced by liberal 
professions. 
 
Additionally, the Commission has stated that as EU competition rules apply to operators 
providing professional services, as they are categorised as undertakings, and it is the 
responsibility of the Commission to ensure this takes place. 
 
5.2.2 Existing literature on impacts of liberalisation 
 
A literature search on PubMed was performed using the search terms “liberal* AND 
community pharma*” and “regulat* AND community pharma*”, all articles and reports 
relating to the impacts or potential impacts of regulation/de-regulation of community 
pharmacy ownership, establishment or distribution found through the search were 
included, as well as relevant references therein. As research on regulation related to the 
pricing and sales of medicines is often linked to these types of studies, they were 
included in the literature review as well. Reports commissioned by the community 
pharmacy sector (“ÖBIG report”, Vogler et al. 2006) as well as the Commission 
(“ECORYS report”, Volkerink et al. 2007) and the UK Office of Fair Trading 
(Mossailos and Mrazek 2003) were also included in the review. 
 
Table 2 summarises the outcomes of various studies and literature reviews, indicating 
also whether the impacts of liberalisation for example are presented as beneficial (pro 
liberalisation) or negative (anti liberalisation). Some of the literature also addresses the 
benefits or disadvantages of maintaining regulation (pro or anti regulation). 
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Table 2 Impacts of regulation and liberalisation reported in literature 
Stated area of 
impact Pro regulation Anti regulation Pro liberalisation Anti liberalisation 
Equity and access 
Regulation* 
increases equity 
and access: Lluch 
2009; Lluch and 
Kanavos 2010 
 
Liberalisation increases 
access and amount of 
pharmacies6: Mossialos 
and Mrazek 2003; Anell 
2005; Wagner et al. 2009; 
Hattingh 2011; Garattini 
et al. 2012; Vogler et al. 
2014 
Liberalisation has decreased 
equity regarding access to 
pharmacies (e.g. through 
pharmacies clustering to urban 
areas): e.g. Vogler et al. 2006; 
Lluch and Kanavos 2010 
Productivity of 
pharmacies  
Regulation 
decreases 
productivity; 
ECORYS report 
2007 
Liberalisation increases 
productivity: ECORYS 
report 2007; Lluch 2009; 
Lluch and Kanavos 2010 
 
Decrease in prices 
of 
pharmaceuticals 
and subsequent 
cost savings 
  
Liberalisation results in 
costs savings (both to 
patient and healthcare): 
Mossialos and Mrazek 
2003 
Prices not found to decrease 
after deregulation: 
Almarsdóttir al 2000; Vogler 
et al. 2006; Stargardt et al. 
2007; Garattini et al. 2012 and 
Vogler et al. 2014 
Increase in 
competition   
Liberalisation increases 
competition: 
e.g. Lluch 2009  
Competition not increased as 
expected following 
liberalisation: Vogler et al. 
2006; Stargardt et al. 2007; 
Garattini et al. 2012; Vogler et 
al. 2014 
Impacts on 
pharmaceutical 
services such as 
patient 
counselling 
  
No decrease in level of 
services following 
liberalisation: 
Almarsdóttir and 
Grimsson 2000; IHS 
report 2003 
Liberalisation could lead to 
deterioration in patient 
counselling: Gidman 2010; 
Kälvemark Sporrong and 
Nordén-Hägg 2014; Vogler et 
al. 2014 
Shift of power 
from individual 
pharmacists to 
large corporate 
chains 
   
Liberalisation leads to a shift 
of power to large corporate 
chains: Mossialos and Mrazek 
2003; Vogler et al. 2006; 
Gidman 2010; Hattingh 2011 
Unintended 
effects such as 
vertical and 
horizontal 
integration 
   
Liberalisation may lead to 
unintended effects such as 
vertical and horizontal 
integration (which could lead 
to product range alignment in 
turn): Anell 2005; Hattingh 
2011; Vogler et al. 2014 
* Regulation of establishment 
                                                
6 though in most cases only in urban areas, if rural areas not specifically protected 
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As can be seen from Table 2 the amount of articles or reports referring to benefits of 
liberalisation is similar to the amount of those addressing its disadvantages (often the 
same study might identify both positive and negative outcomes, depending on the 
indicator as well as the type and level of regulation addressed). 
 
On the other hand, the amount of types of benefits associated to liberalisation is smaller 
than the amount of types of disadvantages. Therefore, there seem to be more arguments 
against liberalisation than for liberalisation, however this does not mean that all 
arguments are similar in proportion or directly comparable in their impact. Also for 
example “No decrease in level of services following liberalisation” was included as a 
reported benefit, even though it is not an argument reflecting positive change but rather 
the opportunity to maintain an important aspect while gaining other benefits and was 
addressed in several studies. 
 
The potential impacts of maintaining regulation or de-regulating addressed were 
grouped under common impact categories Table 2. The column summarising which 
studies present arguments regarding benefits of liberalisation in relation to a certain 
type of impact was deliberately placed next to that presenting arguments regarding its 
disadvantages to demonstrate the heterogeneity of reported impacts. As can be seen, for 
most impact categories there have been both reported benefits and disadvantages 
associated with liberalisation.  
 
For example there are several sources stating that liberalisation increases equity and 
access to pharmacies and pharmaceutical services (Mossialos and Mrazek 2003; Anell 
2005; Wagner et al. 2009; Hattingh 2011; Garattini et al. 2012; Vogler et al. 2014) and 
similarly a number of articles stating the opposite (e.g. Vogler et al. 2006; Lluch and 
Kanavos 2010). As mentioned previously, this partly derives from the fact that different 
studies look at different indicators as well as type and level of regulation. There are also 
differences depending on which country is being studied and also what approach is 
being taken (for example, in some countries access in urban areas might increase 
whereas it might decrease in rural areas at the same time). 
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Positive impacts or expected positive impacts related to liberalisation (including 
disadvantages of maintaining community pharmacy regulation) cover for example 
increased equity and access to patients, increased competition leading to better 
productivity of pharmacies and price reductions resulting in cost savings both for the 
end user as well as the government (ECORYS report 2007; Mossialos and Mrazek 
2003; Anell 2005; Lluch 2009; Wagner et al. 2009; Lluch and Kanavos 2010; Hattingh 
2011; Garattini et al. 2012; Vogler et al. 2014). 
 
Respectively, negative impacts include for example reduced equity or access especially 
in rural areas or for populations with reduced mobility, which could follow from the 
concentration of community pharmacies in high profit areas and reduction in low profit, 
often rural areas (e.g. Vogler et al. 2006; Lluch and Kanavos 2010). Limitations in the 
variety of medicines available has also been observed, which can follow both from 
horizontal integration (pharmacies merging together to form larger corporate 
pharmacies or pharmacy chains) as well as vertical integration (different actors in the 
medicines distribution chain such as producers, wholesalers and pharmacies merging 
together), potentially resulting in limiting competition counter to original aims of 
liberalisation (Anell 2005; Hattingh 2011; Vogler et al. 2014).  
 
This is exemplified through the cases of Norway and Iceland where studies report that 
severe unpredicted outcomes have followed liberalisation, arriving at situations where 
by the year 2004 the pharmacy markets were controlled by two pharmacy groups 
(owning 85% of the Icelandic market) and three pharmacy groups (owning 97% of the 
Norwegian market), respectively, counteracting the initial purpose of increasing 
competition through de-regulation (Anell 2005).  
 
Other reported negative effects of liberalisation include changes in the distribution of 
medicines, such as via online, over country borders, in the case of over-the-counter 
medicines also via parapharmacies and retail outlets, instead of the traditional 
pharmacies (e.g. Vogler et al. 2006). In addition a shift of power from individual 
pharmacists to corporate bodies has been observed (Mossialos and Mrazek 2003; 
Vogler et al. 2006; Gidman 2010; Hattingh 2011). 
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Some of the authors suggest that the above mentioned effects could have detrimental 
effects for public health through reduced access to medicines in rural areas and for 
vulnerable populations, reduction in the range of medicines available and lower level of 
pharmaceutical services. 
 
In summary the body of literature reviewed is heterogeneous pointing to both various 
benefits and disadvantages to de-regulating the community pharmacy sector. For 
example Lluch and Kanavos (2010) note that the establishment rules in place in Spain 
have resulted in better equity among patients regarding access to pharmaceutical 
services compared to UK, which is more liberal in terms of pharmacy establishment, but 
on the other hand the efficiency of pharmacies in UK is reportedly higher, potentially 
deriving from liberalised ownership of pharmacies, compared to Spain. This is further 
disputed by other literature and argumentation related to the professional knowledge 
and responsibility of pharmacists and its relation to limiting pharmacy ownership to 
pharmacists as well as the potential consequences of focusing on productivity leading to 
prioritising economic benefits over patient gain and ultimately public health.  
 
Interestingly, there is evidence to show that liberalisation has in some cases resulted in a 
shift of prioritisation towards economic profitability also leading to stress of the 
personnel providing pharmaceutical services (e.g. Gidman 2010), but there is also not 
much evidence to show that limiting ownership to pharmacists per se is the best way to 
prevent this priority shift or obtain the best possible public health benefit.  
 
This could be studied further to elaborate on whether the existing models in countries 
implementing community pharmacy regulation are the best possible to secure a high 
level of public health, to provide stronger support for the current systems or identify a 
need for improvement. In addition, other aspects should also be taken into 
consideration, such as how to reinforce the level of pharmaceutical services, patient 
counselling and pharmaceutical care, the cornerstone to public health benefits derived 
from the pharmaceutical sector. 
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The key conclusion from most of the literature reviewed seems to be that regardless of 
what is decided on national level, if de-regulation is being planned, potential impacts 
should be carefully considered and a thorough risk-benefit analysis performed prior to 
taking action to ensure that internal market and competition needs are in balance with 
public health needs and any unexpected and unwanted consequences can be prevented 
(Anell 2005; Lluch 2009; Hattingh 2011; Kälvemark Sporrong and Nordén-Hägg 2014; 
Vogler et al. 2014). 
 
5.2.3 The Commission’s liberalisation initiative 
 
In 2003 the Commission started a large-scale initiative to push for deregulation of the 
liberal professions, in order to conform with EU internal market and competition goals 
and specifically the Lisbon agenda where  “the European Council set itself the 
ambitious goal of becoming the most competitive and dynamic knowledge-based 
economy in the world by 2010” (Evans 2003). Commissioner Monti (DG COMP) 
referred to the United States in one of his early speeches in the beginning of the 
liberalisation initiative as an example of a liberal system enabling productivity and 
pleading to Member States and Professionals to take action (Monti 2003b). 
 
Following this, a report was commissioned by the Commission on “Economic impact of 
regulation in the field of liberal professions in different Member States – Regulation of 
Professional Services” (Paterson et al. 2003), which identified pharmacy as one of the 
most regulated professions included in the study, followed by a report: “Study of 
regulatory restrictions in the field of pharmacies” (the “ECORYS report”, Volkerink et 
al. 2007) stating that regulation in the community pharmacy sector reduces productivity 
and that a “reduction of the restrictions to operations leads to a substantial increase in 
social welfare (as a result of a reduction of the so-called dead-weight loss) and 
significantly enhances productivity in the EU”. Both reports were heavily criticised at 
the time for lack of statistic significance and justification (Wilkinson 2014). 
 
Reactions to the report and the Commission initiative by other EU institutions and 
bodies as well as civil society put it high on the European agenda (for example 
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Pharmaceutical Group of the European Union 2006). The Commission systematically 
encouraged Member States to evaluate their legislation in relation to liberal professions 
and to push for de-regulation (Evans 2003; Evans 2005; Monti 2003a; Monti 2003b; 
Kroes 2005a; Kroes 2005b; Dohms 2006; Lowe 2006).  
 
Around the same time several references for preliminary rulings were made to the Court 
of Justice by national courts relating to the natiomossimonal regulations maintained 
regarding the community pharmacy sector. A connection between these cases and the 
Commission’s liberalisation initiative has been identified by some stakeholders and the 
Commission itself has also referred to the outcomes of the cases in relation to 
proceeding with the liberalisation agenda (Wilkinson 2014; European Commission 2015 
a).  
 
In the Commissioner’s opening speech to the European Parliament Juri Committee7 
29.11.2005 Neelie Kroes (Commissioner for DG COMP) clearly stated the objectives of 
the Commission initiative, which are in line with the Lisbon agenda of making the EU 
more competitive: 
 
Our work in the professions is a further contribution to this. It is about better regulation 
of the professions; freeing the sector of unnecessary or overly burdensome rules which 
do not benefit the professions, nor consumers, nor European citizens. More competition 
in this area would be good for the EU economy, promoting cost-efficiency, better 
quality and more innovative services, and increasing demand. 
 
She also made it clear that following the subsidiarity principle Member States should 
themselves review their regulations and using a proportionality test8, evaluate whether 
                                                
7 Committee on Legal Affairs 
8 As stated in a presentation by Dohms (2006): “Proportionality test = core methodology 
checking whether a regulation/rule: 
o has a clearly defined public interest objective, and 
o is objectively at all suitable to achieve this goal, and 
o is the method least restrictive of open markets and competition to achieve this objective” 
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regulations are truly justified by public health benefits and could not be achieved 
through less restrictive means. In addition, she highlighted the need to review territorial 
and quantitative restrictions (applying also to the community pharmacy sector). Lastly, 
she also stated her disappointment in the lack of support and activity on Member State 
level regarding the liberalisation initiative and poor cooperation from the professions 
themselves. 
 
Supposedly due to perceived lack of action on Member State level the Commission 
went on to initiate several infringement proceedings against countries maintaining a 
high level of community pharmacy regulation (Wilkinson 2014), which Commissioner 
Monti brought up as an option in one of his early speeches in the beginning of the 
Commission liberalisation initiative if Member States and the professions themselves 
would not take action: “In the field of liberal professions, we have not yet made much 
use of this power, but the power to act is there” (Monti 2003b). 
 
Response to the Commission initiative 
 
Interest groups representing the “liberalised professions” reacted to the Commission 
initiative in defence of current practice. In the community pharmacy sector this was led 
by the EU-level association representing the sector: PGEU (PGEU 2006). 
  
PGEU commented on the issue as follows (PGEU Press release: PGEU reacts to 
infringement proceedings, 13.7.2006): 
 
The Pharmaceutical Group of the European Union (PGEU) notes the decision of the 
European Commission of 28 June 2006 to take infringement proceedings against the 
governments of Italy, Austria and Spain in connection with certain aspects of domestic 
regulation of the pharmacy sector. 
  
The PGEU believes that EU Member States have the right and the obligation to 
organise their health systems in the interest of their citizens. EU Member States are best 
placed to understand and respond to the needs of their citizens. This is why the EU 
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Treaty retains the organisation of health systems and the delivery of health services as a 
national competence, and why health is considered by the European Court of Justice as 
an issue of overriding importance. PGEU also recalls that the European Parliament 
has recently opposed the inclusion of health services in the Commission proposal for a 
Directive on Services in the internal market. 
 
It goes on to state that access to medicines and independent professional pharmaceutical 
services are integral to European healthcare systems, which is the aim of pharmacy 
regulation in Member States. 
 
There is therefore a clear juxtaposition of internal market and public health interests in 
the debate on liberalisation, even though some public health arguments have also been 
used to promote liberalisation as well.  
 
What then followed was a need to clarify to what extent regulation of the pharmacy 
sector could be justified by public health interests, the Commission and some Member 
States questioning existing regulation and other Member States defending it.  
 
Here the Court of Justice of the European Union cases related to pharmacy regulation 
held a crucial role in creating a precedent to that interpretation. The Court ruled that it is 
up to the Member States to define the extent to which they wish to protect public health 
and the means to obtain this goal, meaning that high regulation of the pharmaceutical 
sector would be justified by public health benefits (as long as it passes the 
proportionality test).  
 
5.2.4 Infringement proceedings against Member State regulation 
 
Following from its liberalisation initiative, the Commission initiated several 
infringement proceedings against Member States such as Austria, Italy and Spain on the 
basis that the national legislation in place regulating the community pharmacy sector 
was infringing community legislation and the fundamental freedoms (Pharmaceutical 
Group of the European Union 2006). 
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However, once the Case C-531/06, Commission of the European Communities v Italian 
Republic, reached its judgment, the Commission dropped all other pending cases 
anticipating similar outcomes. 
 
 
6 AIMS OF THE STUDY 
 
The aim of this qualitative study was to make a critical analysis of the statements linked 
to public health and internal market that are present in the publicly available EU Court 
of Justice documents related to its judgments referring to the regulation of community 
pharmacy establishment, ownership and distribution in EU Member States. 
 
Through the case-study example of the judgments on regulation of community 
pharmacy establishment, ownership and distribution in EU Member States, the 
secondary aim was to discuss their potential impacts on European and national level as 
well as in the broader context of the role of the Court of Justice in EU health policy, 
linking to previous research undertaken in this area. 
 
 
7 MATERIALS AND METHODS 
 
7.1. Study design 
 
The study undertaken was a retrospective qualitative documentary analysis, combining 
both inductive and deductive techniques, complemented by expert interviews (open-
ended semi-structured theme interviews). These are common research methods in the 
field of social pharmacy, combining pharmaceutical aspects with societal research and 
helpful in identifying and understanding emerging phenomena better, which can then be 
supported by quantitative research to define the extent, prevalence and significance of 
the trend or phenomenon (Hämeen-Anttila and Katajavuori 2008). 
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7.2 Materials 
 
The materials for the documentary analysis consisted of documents publicly available 
on the EU Court of Justice website, linked to the judgments on regulation of pharmacy 
establishment, ownership and distribution in EU Member States. These documents 
namely include the Opinions of the Advocate General and the Judgments of the Court. 
All the documents undergoing systematic analysis are listed in Table 3, encompassing a 
total amount of 96 pages of legal text. All the analysed documents were English 
versions, even though some have originally been written in other languages. 
 
Documents included in the literary review covered peer-reviewed scientific articles, 
position papers of interest groups, press releases, news articles as well as legislative text 
ranging from EU Treaties to case-law, which is typical for research including aspects of 
(health) policy. 
 
Lastly, interview records from three expert interviews were also included in the study.  
 
Table 3: List of documents used for documentary analysis 
Case 
number Case Date Subject-matter* 
Documents included 
in analysis 
C-531/06 Commission v Italy 19.5.2009 Freedom of establishment (ownership),  Free movement of capital 
• Opinion 
• Judgment 
C-171/07 
C-172/07 
Apothekerkammer des 
Saarlandes and Others 19.5.2009 Freedom of establishment (ownership) 
• Opinion 
• Judgment 
C-570/07 
C-571/07 
Blanco Pérez and 
Chao Gómez 1.6.2010 Freedom of establishment (distribution) 
• Opinion 
• Judgment 
C-367/12 Sokoll-Seebacher 13.2.2014 Freedom of establishment (distribution), Freedom to provide services • Judgment 
 
* Subject matter according to the Court of Justice, specification added in brackets 
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7.3 Methods 
 
7.3.1 Literature Review 
 
An extensive literature review was performed prior to starting the actual research in 
order to refine the aims of the research as well as understand better the political and 
legal contexts of the research. The literature review specific to impacts of regulation or 
de-regulation in the community pharmacy sector is elaborated in section 5.2.2 of this 
study. 
 
7.3.2 Documentary Analysis 
 
Phase 1 
 
Publicly available material related to the judgments of the Court of Justice of the 
European Union on regulation of pharmacy establishment, ownership and distribution 
issues (available by the end of November 2014 on the CJEU website), namely Opinion 
of Advocate General and Judgment documents, were analysed using inductive content 
analysis as described in Figures 6 and 7 to identify key statements present in the study 
material related to public health and internal market.  
 
Study units (statements with varying length between one sentence and a paragraph) 
were identified and colour coded with a highlighter pen while reading through the 
documents analysed. Selection criteria for study units included that they either referred 
directly to public health (pro, against or neutral) or internal market (pro, against or 
neutral) or clearly implied either.  
 
Next all statements were collected as they originally appear in the research material, in 
chronological order, into a Microsoft Office Word file and their main messages 
summarised (coding). Only statements that were not explicitly referring to existing 
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primary or secondary legislation were included at this point. Similar codes were 
grouped together and organised into categories (“key statements”).  
 
Study units related to public health and internal market referring to existing legislation 
were also identified from the documents and subsequent key statements inductively 
created (“legislation-related key statements”). 
 
Based on the key statements, general themes were created. 
 
Figure 6 demonstrates the inductive analysis process via an example statement. 
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Figure 6 Inductive analysis process demonstrated with an example statement 
1) Identifying study units with colour codes: 
 
 
 
2) Writing down a study unit (statement) and summarising its message: 
 
 
3) Grouping similar messages together to form key statements, and subsequent coding: 
 
 
 
 
 
 
4) Grouping key statements together under general themes:  
As can be seen from Figure 8, the key statement 6) “Pharmacists need professional 
independence to fulfil their [public health] role” falls under the general theme A: “Pro 
regulation of pharmacy ownership for public health reasons” 
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Phase 2 
 
Additionally, all the documents were re-analysed deductively against the key statements 
that had been inductively created on public health and internal market (non legislation 
related), to further evaluate the prevalence of these key statements in the study material 
and to validate results. 
 
Phase 3 
 
Finally, the results were analysed to address what kind of statements related to public 
health and internal market could be found and their prevalence in the study material.  
 
Some general observations were also written down regarding other themes arising from 
the documents, the tone of the documents and so forth, in order to add depth to the 
analysis. All the results were cross-referenced against existing literature regarding the 
role of the Court of Justice in EU health policy to discuss whether signs of spillover 
could be identified and also to debate potential impacts to the community pharmacy 
sector and health policy on national and European level. 
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Data collection 
• Publicly available documents related to the cases downloaded from the 
website of the Court of Justice (n=96 pages) 
• Semi-structured expert interviews conducted (n=3 interviews) 
Reading through all documents 
• Statements (study units) highlighted in colour 
 
Collecting all statements in authentic form 
• All statements were collected as they originally appear in the research 
material, in chronological order into a Microsoft Office Word file 
Coding and summarising 
• Coding was created for each statement to summarise its main message 
 
Grouping 
• Similar codes were grouped together and organised into categories (key 
statements) 
• Key statements referring to existing legislation were inductively created 
Themes 
• Based on the key statements, general themes were created 
Comparing and merging analyses 
• The results of the documentary analysis performed on the CJEU judgement 
documents were compared against existing research 
• All the documents were re-analysed deductively against the key statements 
(non-legislative) that had been inductively created, to further analyse the 
prevalence of these key statements and to validate results 
• Results and general observations emerging from the documentary analysis 
were used as a basis for the structure of the interview framework, material 
from the interviews was used for their validation and elaboration 
Figure 7 Process used for analysis of study data 
Adapted from Elo and Kyngäs 2008 and Kurko et al. 
2012 
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7.3.3 Expert Interviews 
 
In addition to the documentary analysis, some key professionals who had been 
personally involved in the particular Court cases addressed in this study or with special 
expertise in the topic were interviewed to complement and validate the results of the 
documentary analysis. The interviews were open-ended semi-structured theme 
interviews. All interviews were recorded and a summary document was written by the 
interviewer, following each interview. The informants were recruited using purposive 
sampling with the intention to cover as different perspectives to the topic at study as 
possible. Before commencing the interviews it was agreed that the informants would 
remain anonymous, to permit them to speak freely and in that manner assist in the 
ultimate purpose of the interviews: to support and elaborate the findings of the study. 
 
Altogether three expert interviews were undertaken utilising the framework shown in 
Annex 1, based on themes developed through the documentary analysis phase and 
outcomes of the study. During the interviews the framework was used as a basis for 
discussion and questions could be adapted according to the area of expertise of the 
informant where useful. 
 
7.3.4 Ethical Issues 
 
Research of the kind conducted in this study does not require ethical approval in 
Finland, as the documents utilised were all publicly available and the identity of the 
people interviewed was kept anonymous (Finnish Advisory Board on Research Integrity 
2015). The principles of good scientific practice were observed throughout the study. 
 
 
8 RESULTS 
 
8.1 Description of the study population: Cases on community pharmacy regulation 
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8.1.1 Case C-531/06 
 
Case C-531/06 
Commission of the European Communities v Italian Republic 
19 May 2009 
 
Subject matter: Freedom of establishment, Free movement of capital 
 
In this infringement proceeding the Commission requests the Court to declare that the 
Italian Republic has failed to fulfil its obligations under Articles 43 EC and 56 EC by 
maintaining legislation that restricts the right to operate private retail pharmacies only to 
pharmacists and companies or firms run by pharmacists as well as maintaining 
legislative provisions specifically preventing “undertakings engaged in the distribution 
of pharmaceutical products” from acquiring stakes in companies operating municipal 
pharmacies. 
 
The arguments of the Commission include that by keeping such legislation in force the 
Italian Republic is infringing the freedom of establishment and the free movement of 
capital enshrined in Articles 43 EC and 56 EC and that any stated public health 
objectives could be achieved through measures that would limit those freedoms less. 
 
However, the opinion of the Advocate General and the final ruling of the Court were in 
favour of the Italian Republic, stating that as pharmaceutical activities - apart from basic 
tasks of pharmacists - are not harmonised or coordinated on European level, and as it is 
stated in the Treaty, it is up to each Member State to determine the level of protection of 
public health they wish to aim for and the means to reach it and as public health 
overrides other interests according to the Treaty, it is justifiable for a Member State to 
limit the right to operate private pharmacies only to pharmacists and exclude 
distribution undertakings from acquiring stakes in companies operating municipal 
pharmacies. 
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Both the opinion of the advocate general and the final judgment go as far as to describe 
other possible means that Member States could also engage in order to obtain the aim of 
safe medicines provision. 
 
Intervening parties9 to the case include: Greece, Spain, France, Latvia and Austria 
 
8.1.2 Joined Cases C-171/07 and C-172/07 
 
Joined Cases C-171/07 and C-172/07 
Apothekerkammer des Saarlandes and Others 
19 May 2009 
 
Subject matter: Freedom of establishment 
 
In the preliminary ruling procedure the Saarland administrative Court 
(Verwaltungsgericht des Saarlandes) is asking the Court whether the provisions for 
freedom of establishment for companies enshrined in the EC Treaty (according to 
Articles 43 TEC and 48 TEC) should be interpreted as overruling German legislation 
that allows only pharmacists to own and operate a pharmacy and if yes, should the 
national authority then disapply national law where it contradicts Community law. 
 
The background for the preliminary ruling consists of two court cases where The 
Saarland Pharmacists’ Association together with the German Pharmacists’ Association 
and three pharmacists: Ms Schneider, Mr Holzapfel and Mr Trennheuser (Case C-
171/07) as well as Ms Neumann-Seiwert (Case C-172/07) have initiated proceedings 
against Saarland, represented by the Ministry for Justice, Health and Social Affairs, to 
annul the Ministry’s decision to grant DocMorris NV (a Dutch public limited company 
                                                
9 In infringement proceedings only Member States can intervene and provide documentation to support 
the argumentation of the case at hand (Court of Justice of the European Union 2012). Usually Member 
States with similar legislation in place as that of the defendant intervene, to protect their existing 
legislation and prevent a need to change it. 
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operating a mail order business for pharmaceuticals, also joined party to the case) a 
licence to operate a branch pharmacy in Saarbrücken, Germany. 
 
Argumentation for the German legislation in place is based on the Community 
legislation that Member States are allowed to define the extent to which public health 
should be protected and the appropriate ways to achieve this. This is true even if it 
restricts freedom of establishment, as long as it is applied non-discriminatorily, is 
justified on legitimate grounds or by overriding general interest and is suitable for 
obtaining the aim in question without going beyond what is necessary in order to do so. 
 
The opinion of the Advocate General concludes to propose that the Court would rule 
that Articles 43 TEC and 48 TEC should not to be interpreted as overruling the existing 
German legislation that limits the ownership and operating of a pharmacy only to 
pharmacists, based on public health reasons (“ensuring proper provision of medicinal 
products to the public”). The Court (Grand Chamber) ruled in line with this opinion. 
 
Observations were submitted to this case by: 
All parties to the case as well as Germany, Greece, France, Ireland, Italy, the 
Netherlands, Austria, Poland, Finland and the Commission. 
 
8.1.3 Joined Cases C-570/07 and C-571/07 
 
Joined Cases C-570/07 and C-571/07 
José Manuel Blanco Pérez and María del Pilar Chao Gómez v Consejería de Salud 
y Servicios Sanitarios (C-570/07) and Principado de Asturias (C-571/07) 
1 June 2010 
 
Subject matter: Freedom of establishment 
 
In these references for a preliminary ruling the Tribunal Superior de Justicia de Asturias 
(Spain) is seeking to find out whether implementing legislation that restricts the 
establishment of new pharmacies based on the population of a specific area as well as 
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geographically by setting a minimum distance between pharmacies (and public health 
centres) and keeping in place an award system to distinguish between candidates 
competing for a pharmacy licence is precluded by the Article 43 TEC regarding 
freedom of establishment. 
 
The background for the cases is that two Spanish qualified pharmacists (Mr Blanco 
Pérez and Ms Chao Gómez) wanted to open a new pharmacy in the Autonomous 
Community of Asturias, but were not accredited by the Ministry of Health and Public 
Health Services of the Principality of Asturias, the decision of which was later 
confirmed by the Asturian Governing Council. Following this, the aforementioned 
pharmacists disputed the legality of these decisions as well as the restrictions in place 
regarding establishment of pharmacies and the system awarding a licence for a new 
pharmacy as violating their freedom of establishment provided through Article 43 TEC.  
 
The Court rules that even though the implementation of legislation restricting issuing 
licenses for opening new pharmacies (in general one pharmacy per 2800 inhabitants 
with a minimum distance of 250 metres away from any existing pharmacies) does 
contradict the principle of the freedom of establishment, like in the previously addressed 
cases, it is justifiable in order to obtain the public health aim of ensuring safe and 
reliable provision of pharmaceutical services and therefore Article 49 TFEU (ex Article 
43 TEC) does not preclude it as long as exceptions are provided to secure the needs of 
areas with special demographic features. This the Court leaves for the national court to 
determine.  
 
Observations were submitted to this case by: 
All parties to the case as well as the Plataforma para la Libre Apertura de Farmacias, the 
Federación Empresarial de Farmacéuticos Españoles, the Consejo General de Colegios 
Oficiales de Farmacéuticos de España, the Plataforma para la Defensa del Modelo 
Mediterráneo de Farmacias, the Muy Ilustre Colegio Oficial de Farmacéuticos de 
Valencia, the Asociación Nacional de Grandes Empresas de Distribución (ANGED), 
Spain, Belgium, Greece, France, Italy, Austria, Portugal, Slovakia and the Commission. 
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8.1.4 Case C-367/12 
 
Case C-367/12 
Susanne Sokoll-Seebacher 
13 February 2014 
 
Subject matter: Freedom of establishment, Freedom to provide services 
 
In this reference for a preliminary ruling the Unabhängiger Verwaltungssenat des 
Landes Oberösterreich (Austria) is asking the Court to rule on whether Article 16 of the 
Charter of Fundamental Rights of the European Union or Article 49 TFEU (ex Article 
43 TEC) preclude such national legislation that sets criteria for establishment of new 
pharmacies that depends on interpretation (not clearly set in the legislation) and if not, 
whether Article 49 TFEU (specifically the requirement for consistency in achieving the 
desired objective of legislation) precludes such national legislation that sets rigid limits 
to the number of “people remaining to be served” as part of the assessment criteria for 
new pharmacy licenses. 
 
The judgment, following the logic of the previous cases, does not question to public 
health aims of the legislation in place in Austria, but states that it should not be 
implemented (in other words would be precluded by Article 49 TFEU) if the desired 
objective cannot be reached in a consistent manner. In this case it means that the 
objective will not be consistently achieved if there is no room for exceptions to the 
“number of people remaining to be served”-rule, for example in cases of areas of 
“particular local geographical conditions”. 
 
Observations were submitted to this case by: 
All parties to the case as well as Austria, Czech Republic, Portugal and the 
Commission. 
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8.2 Legislative reference 
 
Statements related to public health or internal market with specific reference to 
legislation or case-law were identified separately and developed into key statements, to 
be further grouped under general themes (see next section). 
 
Tables 4 and 5 provide a mapping of all of the legislation-related key statements 
associated with the appropriate legal reference. 
 
Table 4 Legal reference for key statements on public health (legislation related) 
Key statement Referred piece of legislation or case-
law 
Restrictions on freedom of establishment can be justified by overriding 
reasons of general interest such as public health 
Article 52, ex Article 46 TEC 
Public health is a shared competence between Member States and EU, not 
being harmonized it is predominantly a national competence 
Article 168, ex Article 152 TEC 
Protecting human health ranks among the highest priorities of the EU and 
should be implemented in all union policy and action 
Article 35 (Charter of Fundamental 
Rights of the European Union) 
It is up to the member state to decide on matters such as restrictions on 
pharmacies/pharmaceuticals (as long as this is in compliance with the Treaty) 
Directive 2005/36/EC (replacing 
Council Directive 85/432/EEC and 
Council Directive 85/433/EEC) 
“Ensuring that the provision of medicinal products to the public is reliable 
and of good quality” can specifically be used as a justification (reason of 
overriding general interest) for restriction of freedoms of movement 
e.g. Case C-322/01 Deutscher 
Apothekerverband; Case C-141/07 
Commission v Germany 
Member States have the right to decide the extent to which they wish to 
protect public health and determine the methods to obtain this goal 
e.g. Case C-141/07 Commission v 
Germany 
Member States can do this in a preventive manner where there is uncertainty 
regarding the existence or magnitude of a risk to human health 
e.g. Case C-170/04 Rosengren and 
Others 
Due to their therapeutic effects and particular nature, medicinal products 
should be distinguished from other goods 
e.g. Case C-369/88 Delattre 
Due to the safeguards pharmacists must provide and their professional 
obligations, it is justifiable for a Member State to limit the sale of medicinal 
products to pharmacists  
e.g. Case C-369/88 Delattre 
Restrictions in the national legislation are justified by overriding reasons of 
general interest related to public health  
National legislation of case country 
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Table 5 Legal reference for key statements on internal market (legislation related) 
Key statement Referred piece of legislation or 
case-law 
The national legislation restricts freedom of establishment enshrined in the EU 
Treaty 
Article 49, ex Article 43 TEC 
The national legislation restricts free movement of capital enshrined in the EU 
Treaty 
Article 63, ex Article 56 TEC 
Restrictions on free movement of capital can be justified by overriding reasons 
of general interest such as public health 
Article 65, ex Article 58 TEC 
“All measures which prohibit, impede or render less attractive the exercise of 
that freedom must be regarded as such restrictions”, even if they are applied 
without discrimination 
e.g. Case C-442/02 Caixa-Bank 
France; Case C-299/02 
Commission v Netherlands; Case 
C-500/06 Corporación 
Dermoestética 
The national legislation does not fulfil the requirements of being applied in a 
non-discriminatory manner, being justified by imperative requirements in the 
general interest; being suitable for securing the attainment of the objective which 
they pursue; and they not going beyond what is necessary in order to attain it 
e.g. Case C- 19/92 Kraus ν Land 
Baden-Württemberg; Case C-55/94 
Gebhard; Case C-500/06 
Corporación Dermoestética 
Restrictions to freedom of establishment for public health reasons can only be 
justified if the objective cannot be obtained via less restrictive means and they 
could be in the case of the national legislation  
e.g. Case C-140/03 Commission v 
Greece 
“-- national legislation is appropriate for securing attainment of the objective 
relied upon only if it genuinely reflects a concern to attain that objective in a 
consistent and systematic manner” and it is not the case with the national 
legislation  
e.g. Cases C- 338/04, C-359/04 and 
C-360/04 Placanica and Others; 
Case C-169/07 Hartlauer 
Restrictions in the national legislation are not justified (they are not applied 
without discrimination, they are not applied in a consistent manner or they are 
not justified – i.e. the same public health objectives could be  obtained through 
using less restrictive means)  
National legislation of case country 
 
8.3 Key statements 
 
All key statements (both those referring to existing legislation as well as those not 
explicitly referring to legislation) related to public health and internal market 
inductively derived from the EU Court of Justice Documents are listed in Figures 8 to 
11, grouped under general themes. Additionally, for non legislative statements the 
prevalence of original statements falling under each key statement and high level theme 
is also stated in brackets. 
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KEY STATEMENTS – PUBLIC HEALTH (N = 82) 
 
A. Pro regulation of pharmacy ownership for public health reasons (N = 57) 
 
1) The special nature of medicinal products justifies their tighter regulation (5) 
 
2) Pharmacies must be owned by pharmacists to ensure public health interests are in correct balance with 
economic interests (10) 
 
3) Non-pharmacist owners or managers are not bound/”tampered” by the same professional obligations as 
pharmacists and could pressure employed pharmacists to prioritise economic interests over public health 
interests (11) 
 
4) Pharmacists’ economic interests as pharmacy owners are tampered by their professional training, 
experience and responsibility, which if they break will lead to negative consequences (5) 
 
5) Linking professional competence and economic ownership of the pharmacy are justified by public 
health benefits (4) 
 
6) Pharmacists need professional independence to fulfil their [public health] role (6) 
 
7) Preventing manufacturers and wholesalers from getting involved in the ownership of pharmacies is 
justified for public health reasons (protects from risks that could compromise the appropriate level of 
pharmaceutical services being delivered) (11) 
 
8) Full liberalisation of access to the pharmaceutical sector poses a risk for decline in the quality of 
pharmaceutical services (1) 
 
9) Pharmacists working under non-pharmacist employers are not able to pursue their profession with 
total independence (2) 
 
10) Increased competition may lead to a decrease in the level of pharmaceutical services provided to the 
public (1) 
 
11) The national health system at question could go even further in their regulation of the pharmacy 
sector if they wanted, which would still be justifiable by public health reasons  (1) 
 
 
B. Pro regulation of pharmacy distribution for public health reasons 
 
12) Regulating the distribution of pharmacies ensures access to pharmaceutical services, which is 
necessary [promotes public health] (8) 
 
 
C. Others 
 
13) Tasks of pharmacists are not limited to the sale of medicinal products and are done to ensure their 
proper provision, for example via patient information [which should always be neutral and reliable] (8) 
 
14) Strict application of conditions related to demographics without consideration of areas with special 
needs could compromise universal access to pharmaceutical services (8) 
 
15) The quality of the pharmaceutical service provided might be compromised when the pharmacy owner 
of a new pharmacy comes from another area (1) 
 
Figure 8 Key statements related to public health 
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KEY STATEMENTS – PUBLIC HEALTH (legislation related) 
 
A. Public health objectives can justify overriding internal market related 
objectives 
 
1) Restrictions on freedom of establishment can be justified by overriding reasons of general interest such 
as public health 
 
2) Restrictions on free movement of capital can be justified by overriding reasons of general interest such 
as public health 
 
3) Protecting human health ranks among the highest priorities of the EU and should be implemented in all 
union policy and action 
 
4) “Ensuring that the provision of medicinal products to the public is reliable and of good quality” can 
specifically be used as a justification (reason of overriding general interest) for restriction of freedoms of 
movement 
 
5) Restrictions in the national legislation are justified by overriding reasons of general interest related to 
public health  
 
 
B. It is up to Member States to decide on any national regulation on community 
pharmacies 
 
6) Public health is a shared competence between Member States and EU, not being harmonized it is 
predominantly a national competence 
 
7) It is up to the Member State to decide on matters such as restrictions on pharmacies/pharmaceuticals 
(as long as this is in compliance with the Treaty) 
 
 
C. It is up to Member States to define the level and extent of public health 
objectives and the means to pursue them 
 
8) Member States have the right to decide the extent to which they wish to protect public health and 
determine the methods to obtain this goal 
 
9) Member States can do this in a preventive manner where there is uncertainty regarding the existence or 
magnitude of a risk to human health 
 
 
D. Due to the special nature of medicinal products their regulation is justified 
 
10) Due to their therapeutic effects and particular nature, medicinal products should be distinguished 
from other goods 
 
11) Due to the safeguards pharmacists must provide and their professional obligations, it is justifiable for 
a Member State to limit the sale of medicinal products to pharmacists 
 
 Figure 9 Key statements related to public health (legislation related) 
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KEY STATEMENTS – INTERNAL MARKET (N = 32) 
 
A. Pro liberalisation – [there should be no difference between impact on 
public health regardless if the owner of a pharmacy is a pharmacist or not] 
(n = 14) 
 
1) Separation between ownership of the pharmacy and professional functions does not compromise 
public health interests (n=2) 
 
2) There is no evidence to support the claim that pharmacists who are owners of pharmacies would 
be less inclined to let financial interests supersede public health interests  (n=1) 
 
3) Employed pharmacists should follow their professional responsibilities regardless of their 
employer (n=3) 
 
4) Pharmacists also pursue the goal of making financial profit [and may prioritise economic interests 
over public health]  (n=4) 
 
5) Pharmacy owners could be legally prevented from persuading pharmacists to compromise their 
professional obligations (n=1) 
 
6) Pharmacists should not lower the quality of their services as a result of increased competition and 
there exists no evidence to indicate that this would be the case (n=2) 
 
7) Full liberalisation has worked well in some Member States (n=1) 
 
 
B. Pro liberalisation – [pharmacists have limited impact on supplying 
medicinal products and they do not differ in nature from optical products] 
(n = 3) 
 
8) Pharmacists have limited impact in supplying medical products (n=2) 
 
9) Medicinal products are comparable to optical products (n=1) 
 
 
C. Other (n = 15) 
 
10) Pharmacists benefit financially from regulations favouring them and this should be scrutinised [it 
may also indicate regulatory capture, which should be prevented] (n=9) 
 
11) The existing regulations do not ensure the stated public health objectives (n=2) 
 
12) The [Spanish] national legislation results in unequal treatment [against the Treaty and Internal 
Market], which cannot be justified (n=4) 
 
Figure 10 Key statements related to internal market 
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8.3.1  Content and prevalence of statements  
 
8.3.1.1  Reference to origin of statements 
 
There are several statements in the case documents, where a legal reference has been 
explicitly indicated at least somewhere in the document for that specific statement 
(legislation related statements).  
 
For example:  
First, it is clear, both from the case-law of the Court and from Article 152(5) EC and 
recital 26 in the preamble to Directive 2005/36, that Community law does not detract 
from the power of the Member States to organise their social security systems and to 
KEY STATEMENTS – INTERNAL MARKET (legislation related) 
 
A. The national legislation violates fundamental freedoms (internal market 
regulation) 
 
1) The national legislation restricts freedom of establishment enshrined in the EU Treaty 
 
2) The national legislation restricts free movement of capital enshrined in the EU Treaty 
 
3) “All measures which prohibit, impede or render less attractive the exercise of that freedom must be 
regarded as such restrictions”, even if they are applied without discrimination 
 
 
B. The national legislation is not justified 
 
4) The national legislation does not fulfil all the requirements of being applied in a non-discriminatory 
manner, being justified by imperative requirements in the general interest, being suitable for securing the 
attainment of the objective which is pursued and not going beyond what is necessary in order to attain it 
i.e. the restrictions are not justified 
 
5) Restrictions to freedom of establishment for public health reasons can only be justified if the objective 
cannot be obtained via less restrictive means and they could be in the case of the national legislation under 
scrutiny 
 
6) “-- national legislation is appropriate for securing attainment of the objective relied upon only if it 
genuinely reflects a concern to attain that objective in a consistent and systematic manner” and it is not 
the case with the national legislation  
 
 
Figure 11 Key statements related to internal market (legislation related) 
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adopt, in particular, provisions intended to govern the organisation of health services 
such as pharmacies. (Case C-531/06, Commission v Italy) 
 
In addition a number of other statements related to public health and internal market can 
be identified, either referring to opinions and/or materials provided by the parties to the 
cases (opposing parties, interveners, parties in the national cases that have been brought 
to the Court for reference for preliminary ruling) or without reference to any source. 
 
For example:  
In my view, a person who has a pharmacy and is both owner and employer inevitably 
influences the policy followed within the pharmacy in respect of the dispensing of 
medicinal products. (Opinion of advocate general, Case C-531/06, Commission v Italy) 
 
What can be observed directly from Figures 8 to 11 is that there are much more key 
statements that are not directly linked to existing legislation or case-law than those that 
are.  
 
Regarding public health, 15 key statements were derived, that are not directly linked to 
existing legislation, whereas only 11 key statements were identified with reference to 
existing legislation. On the internal market theme the respective numbers were 12 and 6.  
 
This could be seen as rather peculiar, as the task of the Court of Justice of the European 
Union is to base its opinions and following judgments on legislative grounds. It is clear 
that material submitted to the Court should be taken into account in the process, yet the 
line between objectively assessing these submissions and making interpretations 
regarding health policy can be hard to define, as discussed in existing literature. It has 
also been criticised whether the Court has the competence to evaluate research in such 
as specific area as pharmacy or should even have the mandate to do so. On the other 
hand this seems to be the case also in national courts, which have to make decisions 
based on information or reports from a myriad of specific or technical topics. 
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As mentioned earlier, even Advocate Generals have questioned whether the Court is 
addressing issues, which should be dealt with by national courts (e.g. Opinion of 
Advocate General for joined Cases C‐159/12, C‐160/12 and C‐161/12 Venturini and 
Others). It is clear that the CJEU is a needed and powerful tool in interpreting and 
implementing European legislation, however it would be important to ensure that the 
impact of its work follows the original intention behind its establishment. 
 
8.3.1.2  Public health v internal market 
 
There is a significantly higher amount of statements related to public health, and 
specifically pro public health, than those related to internal market. For example, the 
amount of key statements related to public health (non legislation related) is 15, 
deriving from 82 original statements, compared to 12 key statements related to internal 
market (non legislation related) and 32 original statements. In other words there were 
over twice as many original statements and slightly more key statements (i.e. argument 
categories) related to public health (non legislation related) than internal market. 
 
Regarding legislation related statements there were altogether 11 key statements related 
to public health can be identified and respectively 6 key statements related to internal 
market, reflecting the same trend as with non legislation related statements. 
 
It is interesting to note that the argumentation for or against maintaining national 
regulation is mainly based on public health argumentation. This could derive for 
example from argumentation in previous case law, the clear prioritisation of the 
protection of public health stated in EU legislation or other reasons. Also it is 
noteworthy to mention that not only did the documents contain a strong presence of pro 
public health statements, but some Opinions of the Advocate General and consecutive 
Judgments went even so far as to propose other options of regulation that the Member 
State could pursue, if they so wished.  
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An example of such a statement is found in Case C-531/06 Commission v Italy 
(Opinion of Advocate General): 
 
Following the example of other Member States, the Italian legislature could also have 
adopted another system and chosen to protect public health by other means, for 
example by making just the opening of new pharmacies subject to the fulfilment of 
conditions regarding their geographical distribution, to the existence of a certain 
number of inhabitants per pharmacy or to rules relating to observance of a minimum 
distance between two pharmacies. Among other measures designed to ensure that the 
objective of protection of public health takes priority over economic interests, a 
Member State might choose to keep the monopoly on the sale of medicinal products by 
pharmacists and/or decide to regulate the price of medicinal products. 
 
The most common key statements found in the study material were: “Non-pharmacist 
owners or managers are not bound/”tampered” by the same professional obligations as 
pharmacists and could pressure employed pharmacists to prioritise economic interests 
over public health interests” and “Preventing manufacturers and wholesalers from 
getting involved in the ownership of pharmacies is justified for public health reasons 
(protects from risks that could compromise the appropriate level of pharmaceutical 
services being delivered)”.  
 
Following this, what seemed to become the pivotal argument in most Court of Justice 
cases was indeed whether the claimed professionalism inherent in pharmacy is strong 
enough to justify restricting certain privileges only to pharmacists. 
 
8.3.1.3  Outcomes of cases 
 
Ultimately the Court ruled in favour of maintaining existing national regulation 
regardless of the extent or type of regulation, justifying this by overriding public health 
interest and the right for Member States to determine the level of public health 
protection and means to obtain it. This applied throughout all cases studies, as long as it 
was applied in a consistent manner and without discrimination.  
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This means that the Court of Justice did not question the public health argumentation in 
any of the Cases. What it did question, however, was for example the competition 
procedure for a new pharmacy licence maintained in Asturias, Spain (joined Cases C-
570/07 and C-571/07 Blanco Pérez and Chao Gómez), providing advantage to those 
candidates who have practiced in Asturias previously and implying discrimination 
based on country of origin. Also, the establishment criteria in place in the same case 
were called to question to the extent as to if they would be implemented without 
exception in cases concerning areas with special needs. This thinking was also followed 
for example in the later Case C-367/12 Sokoll-Seebacher, the Court stating that if the 
establishment criterion related to the “number of ‘people remaining to be served’” were 
to be applied without exception or consideration of areas with special population needs 
(isolated or rural areas, people with reduced mobility) it “gives rise to a danger that 
equal and adequate access may not be guaranteed”. The interpretations stated above, 
regarding the outcomes of the cases have also been supported by Baeten and Palm 
(2011). 
 
The reasons why the Court of Justice ruled for maintaining national regulation and 
therefore pro very strong public health statements could be various. According to one of 
the expert interviews for this was not expected to be the outcome in the joined Cases C-
570/07 and C-571/07 Blanco Pérez and Chao Gómez, as the Opinion of the Advocate 
General was much more negative in tone and critical of the role of pharmacists in 
protecting public health, especially through limiting ownership of pharmacies to 
pharmacists based on public health reasoning. 
 
On one hand it was clearly stated that the level of protection of public health and 
determining the means to reach this is up to Member States to decide, so the outcomes 
could be seen as a result of the Court of Justice following this logic as far as possible. 
On the other hand it has been observed that the Court of Justice tends to rule pro 
existing national legislation where it can, in order not to provoke legislative change 
unless it is unavoidable (Lluch 2009). This observation was however questioned in the 
discussion taking place during one of the expert interviews, where the informant 
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expressed that according to their experience the Court has not in general been afraid to 
make rulings implying significant legislative change on national level. 
 
Based on the expert interviews conducted for this study, it also seems that some 
stakeholders perceive the Court of Justice as a sort of balancing power to the 
Commission, as the Commission has such a strong mandate to pursue issues that fall 
under extensive EU competence such as internal market and therefore a “counterforce” 
is needed, especially in mediating between national and supranational competence.  
 
In one of the interviews the informant commented that even though the Court of Justice 
is a neutral body, it does not exist in a vacuum, so even if it would not intentionally be 
part of its thinking process, the Court must have been aware of the political climate and 
actions taking place on European level at the time of most of the cases studied and this 
could have also had an impact, just like any other external factors occurring in the 
surrounding society. 
 
8.3.2 General observations 
 
General observations regarding the materials included in the documentary analysis were 
mainly related to their tone and style of argumentation, especially the Opinions of the 
Advocates General included statements and argumentation that could be described as 
rather “passionate”, bordering on lyrical at times – for example the Opinion of the 
Advocate General for the joined cases C-570/07 and C-571/07 Blanco Pérez and Chao 
Gómez goes on to cite William Shakespeare’s Romeo and Juliet to emphasise one of the 
thesis arguments. Based on the expert interviews this is not an uncommon phenomenon. 
 
In addition to the themes under study relating to public health and internal market two 
other themes of interest seemed to recur in all cases in the form of statements related to 
community pharmacists (or the pharmaceutical profession in general) and economical 
issues. 
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8.3.2.1 “The concern that pharmacists in need of money may compromise their 
professional obligations is not new” – comments regarding pharmacists 
 
As mentioned earlier, the question of whether the education and professional obligation 
to prioritise patient benefit inherent to pharmacists as a regulated health profession 
justifies elaborate regulations on national level became one of the crucial questions in 
the cases studied. The Opinions of the Advocate General and consecutive Judgments of 
the Court in the first two cases (C-531/06 Commission v Italy and joined cases C-
171/07 and C-172/07 Apothekerkammer des Saarlandes and Others) were more positive 
in tone regarding statements related to pharmacists and therefore supportive of the 
linkage between the professionalism of pharmacists and public health benefit. 
 
An example of such a statement is: 
I also consider that a pharmacist’s duty to give advice is very important in the case of 
over-the- counter medicines, the number of which is constantly increasing as a result of 
decisions taken by States in order to maintain the balance of the welfare budget. In 
those circumstances, a patient can rely only on the information provided by the health 
professional, the pharmacist. (Opinion of Advocate General for case C-531/06 
Commission v Italy) 
 
The Opinion of the Advocate General for the joined cases C-570/07 and C-571/07 
Blanco Pérez and Chao Gómez on the other hand could be interpreted as more negative 
in tone regarding statements related to pharmacists and indicated that pharmacists 
would be as susceptible to prioritise economic benefits over public health benefits as 
any other professionals. 
 
The citation included in the heading of this section is from the Opinion of the Advocate 
General to this case and continues: “-- It has been a matter of concern at least since 
Shakespeare’s Romeo convinced a ‘caitiff wretch’ of an apothecary to sell him poison --
” 
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In the end the following judgment respected the logic that had been established in the 
previous cases, not questioning the public health argumentation behind national 
legislation in place. 
 
The last case (Case C-367/12) included only the judgment and similarly followed the 
argumentation present in preceding case-law. 
 
8.3.2.2 “the pharmaceutical sector generates considerable costs and must satisfy 
increasing needs” – comments regarding economic aspects 
 
Statements regarding economic aspects can be found in most of the cases as well, which 
could be seen as rather surprising as it is not a key element of the core questions 
addressed in the cases. In the literature addressing impacts or potential impacts of 
pharmacy regulation or liberalisation economic considerations (mostly benefits) are 
usually associated with arguments pro liberalisation. However, in the Court of Justice 
documents they seem to be used mostly to support public health statements, such as in 
the following examples: 
 
Also, the unregulated opening of new pharmacies might trigger an increase in 
pharmaceutical costs. (Opinion of Advocate General for case C-531/06 Commission v 
Italy) 
 
I also consider that a pharmacist’s duty to give advice is very important in the case of 
over-the-counter medicines, the number of which is constantly increasing as a result of 
decisions taken by States in order to maintain the balance of the welfare budget. 
(Opinion of Advocate General for case C-531/06 Commission v Italy) 
 
Overconsumption or incorrect use of medicinal products leads, moreover, to a waste of 
financial resources -- (Judgment for case C-531/06 Commission v Italy) 
 
In the light of those risks to public health and to the financial balance of social security 
systems, the Member States may make persons entrusted with the retail supply of 
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medicinal products subject to strict requirements, including as regards the way in which 
the products are marketed and the pursuit of profit. (Judgment for joined cases C-
171/07 and C-172/07 Apothekerkammer des Saarlandes and Others) 
 
In particular, ‘interests of an economic nature concerning the maintenance of a 
balanced medical and hospital service open to all’ may present a suitable public 
interest. (Opinion of Advocate General for joined cases C-570/07 and C-571/07 Blanco 
Pérez and Chao Gómez) 
 
8.4 Expert interviews 
 
Outcomes of the expert interviews seemed to be in line with the general thinking behind 
this research and its main conclusions.  
 
The interviews provided particular support and additional clarity in the following areas: 
 
• Climate and political background giving rise to the cases 
• Understanding the processes of the EU institutions 
• Understanding the processes of the Court of Justice 
• Raising awareness of further actions following the cases studied as well as 
actions taking place related to the liberalisation debate that have not yet been 
reported 
• Elaborating on EU legislative procedure and dynamics between the different 
actors 
 
All the information collected via the interviews helped to put the different pieces of the 
study together and into the greater context of EU health policy. Results from previous 
interviews also helped to shape the discussion in the following interviews. It was also 
extremely helpful that the informants represented different perspectives and professions, 
greatly assisting to form as complete a picture as possible in regards to the relatively 
complex topic at hand. 
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9 DISCUSSION 
 
9.1 Outcomes of documentary analysis 
 
A higher number of both original statements as well key statements were identified 
when comparing the prevalence of public health related statements to internal market 
related statements in the documents analysed. Additionally, the prevalence of non-
legislation related key statements appeared to be higher than of those directly related to 
legislation. Some potential reasons for this were already addressed.  
 
Regardless of the reasons behind the higher prevalence of public health statements, 
through the strong pro public health argumentation and the following Court of Justice 
judgments supporting national regulation aiming at the protection of public health to as 
high a level as needed, it is clear that it does send a certain signal regarding the balance 
and prioritisation between public health and internal market interests, ultimately having 
an impact on health policy at a European level. 
 
The argumentation used in the court case documents seems to be also more in line with 
that of the literature supporting pharmacy regulation or criticising liberalisation. From 
this perspective it would support the suggestion highlighted in the expert interviews of 
this study that in the public health versus internal market interphase, the Court has taken 
a balancing role to that of the Commission, be it intentional or not.  
 
According to the expert interviews this is not the case in all areas, however public 
health is a rather particular area in the sense that it has been given a highest possible 
priority in the Treaty, but ultimately not much assistance for practical interpretation has 
been provided through secondary legislation for example, largely due to the Member 
States’ reluctance to give up their competence on health. Therefore it would be logical 
for the Court would protect this priority. 
 
What this leads to, is that most of the reasoning arriving at the conclusion that the 
restrictions maintained in the different Member States are justified, comes from 
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previous Court case-law. As there exists relatively little legislation related to health on 
European level to use as basis for case-law, it means that the reasoning in the case-law 
has in fact been largely developed by the Court of Justice itself. According to the expert 
interviews this phenomenon has been recognised in completely different sectors as well 
and seems to be typical for areas that lack comprehensive EU legislation, which would 
give proper guidance.  
 
This circles back to the question on whether the decision making processes and other 
processes currently shaping the European healthcare policy are in line with what was 
originally intended and would suggest a need to re-evaluate whether this dynamic is the 
preferred way to proceed in the future. Civil society has called for increased awareness, 
transparency and democracy in this area as well as involvement of people with 
competence in health care. Even though questions have been raised whether the Court 
of Justice for example has the competence to evaluate public health research and make 
decisions based on it, the situation will not change unless the underlying dynamic is 
modified.  
 
9.2 Impact on community pharmacy 
 
At the core of the cases studied was the question that even though it is up to Member 
States to decide how to set up their healthcare systems and regulate issues related to 
them, whether those restrictions can be seen as justified and implemented in an coherent 
manner. The role of pharmacists as a regulated profession in relation to this question 
was also highlighted. 
 
The Court cases included in this study, through their judgments have now established a 
strong precedent for interpretation supporting a high level of community pharmacy 
regulation on national level, based on arguments related to the protection of public 
health and the central role of pharmacists in this (at least as providers of pharmaceutical 
services). In its argumentation the Court goes as far as to even suggest further options 
for regulation the countries could adopt in order to protect the public health objective of 
reliable and good provision of medicinal products to the public.  
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There have been similar court cases to the ones included in the study, which have been 
resolved in the same fashion (pro national regulation if it is implemented in a consistent 
manner and without discrimination, not questioning extent of public health objectives or 
means to obtain them), without a need for judgment. The Court may follow this 
procedure when the existing case-law is perceived as undisputable in its interpretation. 
There have been also other cases with some similar elements, concerning for example 
parapharmacies (e.g. Joined Cases C‐159/12, C‐160/12 and C‐161/12 Venturini and 
Others) and branch pharmacies (e.g. Case C-84/11 Susisalo and Others), which both 
employ similar argumentation to that identified in the cases studied. 
 
Following from this, it is rather safe to assume that it is unlikely that the legal 
interpretation would change in the near future and in that sense Member States can 
expect to be allowed to continue maintaining their existing community pharmacy 
legislation, as long as it does not violate EU legislation in other ways or lack 
consistency in its implementation. According to the expert interviews conducted, the 
most likely way this interpretation could be changed would be through actual secondary 
EU legislation or a change in the Treaties. 
 
As the Court of Justice follows existing case-law in its interpretation, the first cases 
related to a certain area or phenomenon have a crucial role to play. According to expert 
interviews, when new or complex issues are brought to the Court an Advocate General 
is used to provide a neutral and thorough analysis of all the aspects of the case and 
therefore their opinion carries much weight in steering the direction of the Court (even 
though the final judgments do not always follow the opinion of the Advocate General, 
but this is relatively rare). Therefore, considering the difference in tone between 
Opinions of the Advocates General included in the study, one could pose the 
hypothetical question of whether the cases might have resulted differently, had their 
order been different. In practice this is not relevant as the established case-law is strong 
in its interpretation and should be followed accordingly. 
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9.3 Push for liberalisation continues – the discussion is not over 
 
Even though Court judgments supported maintaining national regulations, it has been 
demonstrated that the Commission has moved to utilising other avenues to push for 
deregulation. A concrete example of this would be the Country Specific 
Recommendations (CSR: s)10 that the EU issues to Member States in relation to its 
fiscal governance (the European Semester), often containing elaborate instructions 
related to health care. For example the 2013 CSR: s to France included the following 
statement: “--increase the cost-effectiveness of healthcare expenditure, including in the 
areas of pharmaceutical spending” (European Commission 2015c).  
 
Further to this Member States that have become part of the EU bailout-programmes 
following financial crisis have been subjected to economic adjustment programmes by 
the “Troika11”, that issue detailed recommendations and milestones concerning 
healthcare systems, which the countries have to commit to in return for financial 
support (European Commission 2014d). The economic adjustment programme for 
Greece12 for example included particular instructions related to pharmaceutical pricing 
and spending, as well as liberalisation of OTC sales (if increased competition in the 
OTC sector does not lead to significant price reductions) (European Commission 
2014d). 
 
Additionally, it was brought up in the expert interviews, that in fact there would 
currently be an infringement proceeding initiated by the Commission against Hungary 
in relation to establishment criteria. The proceedings have not yet reached the phase in 
                                                
10 All CSR: s may be found at: European Commission: European Semester 2015. Brussels, European 
Commission 2015c [accessed online 15.5.2015: http://ec.europa.eu/europe2020/making-it-
happen/country-specific-recommendations/index_en.htm] 
11 The “Troika” refers to the three creditor institutions in the country bailout programmes: the European 
Commission, the European Central Bank and the International Monetary Fund  
12 Further information for example in: European Commission: The Second Economic Adjustment 
Programme for Greece. Fourth Review. Brussels, European Commission 2014d [accessed online 
15.5.2015: http://ec.europa.eu/economy_finance/publications/occasional_paper/2014/pdf/ocp192_en.pdf] 
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which public notice should be made, but it is something that would be relevant to follow 
in the context of this research. 
 
9.4 Limitations of the study – validity and reliability 
 
The analyses were performed and interviews conducted by the same person, which 
reduces risk of variability between treatment of study materials, but on the other hand 
introduces a risk of bias in interpreting results. 
 
On the other hand there is always some subjectivity included in the method used in this 
study, as it is up to the researcher to evaluate when a study unit matches the required 
criteria and should be included, as well as to summarise and group together statements 
in the way that seems most logical. What could be done to reduce subjectivity could be 
to have two researchers go through all the same documents and compare results, 
discussing together the ones that differ to agree whether they should be included or not, 
as well as working together in the next phases of the documentary analysis. Even in this 
solution would not remove the subjectivity inherent in the method used, but could 
decrease it. 
 
This is common for qualitative research as ultimately the objective is to describe a 
phenomenon and distinguish trends rather than produce en exhaustive data set. 
Qualitative research can then be supplemented with quantitative research (or vice versa) 
to truly give an accurate, yet in-depth picture of the phenomenon under research. 
 
For the purposes of this research it was necessary to identify the trends within the 
documents analysed, both in terms of content and prevalence, in order to evaluate 
against the aims of the research and therefore the method can be considered valid for the 
purposes of this research. 
 
To ensure the validity of the methodology it was also discussed with the thesis 
instructors (university research staff) prior to starting the research. The interview 
framework was also reviewed by the instructors. 
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Regarding the brevity of the research material, the scope of the material included in the 
documentary analysis was limited mainly to legal Court documents available to the 
general public. Therefore it should be acknowledged that the background 
documentation for the cases, in other words the submissions provided by the parties to 
the cases or the national cases referred to the Court, were not included as they are not 
publicly available. For the purposes of the study this was not necessary, as the objective 
was to analyse what statements are present in the ECJ documents regardless of their 
origin. However, it would be interesting to perform a similar analysis on the background 
documentation as was done to the court documents and compare results to see where 
some of the statements might have originated from. This would however require access 
to all of the background documentation of all cases to have a complete picture, which 
might be hard to obtain.  
 
This is of course still not completely reliable as there is a lot of circulation of arguments 
and phraseology on both European and national level and it might be hard to pinpoint 
where an argument has originated from, even if one party would be using it at the time 
of research. 
 
Additionally, in order to maintain a clear scope for the research, only Court cases 
directly dealing with regulation of pharmacy establishment, ownership and distribution 
in EU Member States were included in the main analysis. Reference to other related 
cases, such as for regulation of branch pharmacies or parapharmacies as well as for 
cases for regulation of other sectors could then be made on a more general level to 
discuss what similarities could be perceived and their potential meaning.  
 
Only cases resulting in a Judgment were included, as they define how following cases 
should be resolved. Therefore any similar statements resolved via an order should 
reflect the same arguments as those present in the judgment. For completeness this 
could be studied and evaluated in the future. 
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Informants and materials for the documentary analysis were chosen by purposive 
sampling due to the specific nature of the topic. The informants were chosen in a 
manner to cover as many different viewpoints as possible to provide as neutral and 
complete a picture of the study subject as possible. 
 
Due to no prior involvement of the researcher in the cases studied or activity in the 
particular topic of community pharmacy regulation this enabled a more neutral 
approach to be taken to the topic. 
 
9.5 Uses of the study and further research 
 
This study supplements and supports existing literature in the broader context of the role 
of the Court of Justice of the European Union in developing public health policy in 
Europe, highlighting the need for raising awareness and evaluating the current dynamic 
behind health policy and legislation. 
 
Through the focus study of the Court cases related to the regulation of community 
pharmacy establishment, ownership and distribution this research elaborates on the 
argumentation used for and against maintaining national regulation in the cases as well 
as linking it to the broader existing literature.  
 
It seems that even though the Court of Justice Cases addressed in this study have indeed 
been referred to by several sources, no systematic review including all of them and / or 
utilising scientific research methodology has been published to date, meaning that this 
study would hopefully bring added value to the existing body of literature. 
 
Potential future approaches to add to this particular research have been identified in 
section 9.4. On a more general level there is a clear need to follow future developments 
in this area and to generate robust, neutral and statistically significant evidence to back 
on-going debates.  Lastly, in addition to focusing on implications or potential 
implications of de-regulating the sector, it would be equally important to work on 
generating additional research to identify what are the best ways to support and enable 
 84 
the public health objectives pursued by the community pharmacy sector in a way that 
balances efficiency of pharmacy operation with the benefit of the patient.  
 
It is also important that this is all put in context of the whole healthcare chain - it is for 
example easy to say that medicines create costs but when compared to costs of 
hospitalisation for they are much less burdensome. As mentioned by several sources, 
countries are increasingly focusing on self-care and therefore moving the onus of 
healthcare to community pharmacies. Therefore investing in proper pharmaceutical 
services can pay itself back many times over when looking at the bigger picture of 
healthcare systems. 
 
 
10 CONCLUSIONS 
 
In the European Union setting the Commission has heavily argued for the benefits of 
liberalising the community pharmacy sector, following its mandate to promote internal 
market and competition. This has been criticised by the community pharmacy sector, 
demonstrating that many of the intended benefits of liberalisation have not been realised 
in countries where it has been implemented. The body of literature analysed on the 
impacts or potential impacts of liberalisation suggests that there have been both 
negative and positive effects following liberalisation in Member States. Further research 
would be needed to define what is the best way to support the national public health 
objectives through community pharmacy activity in a way that balances patient interest 
and efficiency. Emphasis should also be put on pharmaceutical services and care, which 
have been pointed out as the cornerstones to the public health benefit of pharmacists 
and pharmacies, and yet are reportedly still being provided to a limited extent.  
 
Due to limited legislation on healthcare and public health on European level, the Court 
of Justice of the European Union has played a key role in defining interpretation 
between conflicting EU internal market regulation and Member State legislation where 
it implies regulation of the community pharmacy sector. Through a handful of cases and 
their consecutive judgments the Court has created a body of case-law in support of 
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national regulation, based on the argumentation that it is up to Member States to define 
the level of protection of public health they wish to aim for - no matter how high it may 
be - and the means to obtain it. The argumentation present in the judgments sends a 
clear message on the importance of public health and indeed the Court has been 
perceived as a balancing force of sorts to the Commission’s liberalisation agenda. 
 
Following this it seems unlikely that the interpretation for national regulation would 
change in the near future, meaning that Member States should be able to maintain 
community pharmacy regulation to the extent that it is implemented in a consistent 
manner and does not violate any other EU legislation. However, there has been 
indication of other routes being used to push for the liberalisation agenda and therefore 
it continues being a part of the debate at both European and national level. 
 
Ultimately both the Commission and the Court of Justice are performing the tasks they 
have been originally mandated to do by the Member States, but due to gaps in the 
current legislative and decision making structure this has lead to increased impact in 
areas that might have not originally been intended. This together with the findings of the 
study support the claim that there is indeed functional spillover taking place in relation 
to the work of the Court of Justice and specifically related to the case of community 
pharmacy and public health. 
 
It has been clearly demonstrated that even though officially the EU has very limited 
competence in health, its influence on European health policy is in fact highly 
significant, taking place to a large extent via routes other than those officially assigned 
to it in relation to health in particular. Whether this is intentional or unintentional, it 
does not change the fact that it is being influenced. When it happens without explicit 
intention, the processes lose transparency and are driven by other, potentially competing 
agendas. Therefore it would be important to assess whether the decision making 
processes and other processes currently shaping the European healthcare policy are in 
line with what was originally intended and re-evaluate whether this dynamic is the 
preferred way to proceed in the future. 
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ANNEXES 
 
ANNEX 1 Interview framework 
 
 
 
INTERVIEW FRAMEWORK 
 
 
1. Are you familiar with the Court of Justice of the European Union judgments related to regulation of 
community pharmacy establishment, ownership and distribution? If yes, could you briefly describe 
in your own words the background behind them? 
 
2. Could you briefly describe in your own words the key arguments in the cases [prompt: related to 
public health and internal market]? 
3. Are you aware of any similar Court of Justice cases in other sectors? 
4. Through analysing the opinions of the advocate generals and the CJEU judgments regarding 
pharmacy regulation, it becomes evident that they include rather strong statements related to public 
health (and pharmacists), which cannot be only explained through previous case law or European 
legislation. Where do you think these statements come from?  
5. What do you think is the meaning/implication of this [having clear case-law on the issues] to 
Member States and the community pharmacy sector? 
6. What about the impact on European health policy in a broader context? 
7. Could the message and effects of this be linked also to the message and effects of pharmaceuticals 
staying in DG SANTE? [regardless of the reasons behind, it sends a certain message to the public 
regarding the balance between public health and internal market] 
8. Do you think the Court of Justice has an increasing impact on shaping European health policy? [e.g. 
through these judgments shift the balance between internal market and public health, could 
potentially be seen as a “counterweight” to the Commission] 
9. Is there anything else you would like to add that might be interesting to take into account in the 
research? 
